{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T18:12:48Z","timestamp":1778695968470,"version":"3.51.4"},"reference-count":533,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:00:00Z","timestamp":1615939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100018353","name":"European Crohn's and Colitis Organization","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018353","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,22]]},"DOI":"10.1093\/ecco-jcc\/jjab052","type":"journal-article","created":{"date-parts":[[2021,3,13]],"date-time":"2021-03-13T12:11:03Z","timestamp":1615637463000},"page":"879-913","source":"Crossref","is-referenced-by-count":408,"title":["ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease"],"prefix":"10.1093","volume":"15","author":[{"given":"T","family":"Kucharzik","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Klinikum L\u00fcneburg, University of Hamburg , L\u00fcneburg , Germany"}]},{"given":"P","family":"Ellul","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, Mater Dei Hospital , Msida , Malta"}]},{"given":"T","family":"Greuter","sequence":"additional","affiliation":[{"name":"University Hospital Z\u00fcrich, Department of Gastroenterology and Hepatology, Z\u00fcrich, Switzerland, and Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois CHUV, University Hospital Lausanne , Lausanne , Switzerland"}]},{"given":"J F","family":"Rahier","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, CHU UCL Namur , Yvoir , Belgium"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3898-7093","authenticated-orcid":false,"given":"B","family":"Verstockt","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium, and Department of Chronic Diseases, Metabolism and Ageing, TARGID-IBD , KU Leuven, Leuven , Belgium"}]},{"given":"C","family":"Abreu","sequence":"additional","affiliation":[{"name":"Infectious Diseases Service, Centro Hospitalar Universit\u00e1rio S\u00e3o Jo\u00e3o , Porto , Portugal"},{"name":"Instituto de Inova\u00e7\u00e3o e Investiga\u00e7\u00e3o em Sa\u00fade [I3s], Faculty of Medicine, Department of Medicine, University of Porto , Portugal"}]},{"given":"A","family":"Albuquerque","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, St James University Hospital , Leeds , UK"}]},{"given":"M","family":"Allocca","sequence":"additional","affiliation":[{"name":"Humanitas Clinical and Research Center \u2013 IRCCS - , Rozzano [Mi] , Italy"},{"name":"Humanitas University, Department of Biomedical Sciences , Milan , Italy"}]},{"given":"M","family":"Esteve","sequence":"additional","affiliation":[{"name":"Hospital Universitari M\u00fatua Terrassa, Digestive Diseases Department, Terrassa, Catalonia, and Centro de Investigaci\u00f3n Biom\u00e9dica en red de Enfermedades Hep\u00e1ticas y Digestivas CIBERehd , Madrid , Spain"}]},{"given":"F A","family":"Farraye","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Center, Department of Gastroenterology and Hepatology, Mayo Clinic , Jacksonville, FL , USA"}]},{"given":"H","family":"Gordon","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Barts Health NHS Trust, Royal London Hospital , London , UK"}]},{"given":"K","family":"Karmiris","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Venizeleio General Hospital , Heraklion , Greece"}]},{"given":"U","family":"Kopylov","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sheba Medical Center, Ramat Gan, Israel, and Sackler School of Medicine, Tel-Aviv University , Tel-Aviv , Israel"}]},{"given":"J","family":"Kirchgesner","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pital Saint-Antoine, Department of Gastroenterology , Paris , France"}]},{"given":"E","family":"MacMahon","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , London , UK"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2634-9668","authenticated-orcid":false,"given":"F","family":"Magro","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Centro Hospitalar S\u00e3o Jo\u00e3o , Porto , Portugal"},{"name":"Institute of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto , Portugal"}]},{"given":"C","family":"Maaser","sequence":"additional","affiliation":[{"name":"Outpatient Department of Gastroenterology, Department of Geriatrics, Klinikum L\u00fcneburg, University of Hamburg , L\u00fcneburg , Germany"}]},{"given":"L","family":"de Ridder","sequence":"additional","affiliation":[{"name":"Department of Paediatric Gastroenterology, Erasmus MC-Sophia Children\u2019s Hospital , Rotterdam , The Netherlands"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9166-7350","authenticated-orcid":false,"given":"C","family":"Taxonera","sequence":"additional","affiliation":[{"name":"IBD Unit, Department of Gastroenterology, Hospital Cl\u00ednico San Carlos and Instituto de Investigaci\u00f3n del Hospital Cl\u00ednico San Carlos [IdISSC] , Madrid , Spain"}]},{"given":"M","family":"Toruner","sequence":"additional","affiliation":[{"name":"Ankara University School of Medicine, Department of Gastroenterology , Ankara , Turkey"}]},{"given":"L","family":"Tremblay","sequence":"additional","affiliation":[{"name":"Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al [CHUM] Pharmacy Department and Faculty of Pharmacy, Universit\u00e9 de Montr\u00e9al , Montr\u00e9al, QC , Canada"}]},{"given":"M","family":"Scharl","sequence":"additional","affiliation":[{"name":"University Hospital Z\u00fcrich, Department of Gastroenterology and Hepatology , Z\u00fcrich , Switzerland"}]},{"given":"N","family":"Viget","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Tourcoing Hospital , Tourcoing , France"}]},{"given":"Y","family":"Zabana","sequence":"additional","affiliation":[{"name":"Hospital Universitari M\u00fatua Terrassa, Digestive Diseases Department, Terrassa, Catalonia, and Centro de Investigaci\u00f3n Biom\u00e9dica en red de Enfermedades Hep\u00e1ticas y Digestivas CIBERehd , Madrid , Spain"}]},{"given":"S","family":"Vavricka","sequence":"additional","affiliation":[{"name":"University Hospital Z\u00fcrich, Department of Gastroenterology and Hepatology , Z\u00fcrich , Switzerland"}]}],"member":"286","published-online":{"date-parts":[[2021,3,17]]},"reference":[{"key":"2022082312072164400_CIT0001","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.crohns.2009.02.010","article-title":"European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"3","author":"Rahier","year":"2009","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0002","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","article-title":"Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"8","author":"Rahier","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0003","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/MIB.0b013e3182a827d2","article-title":"Opportunistic infections due to inflammatory bowel disease therapy","volume":"20","author":"Dave","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0004","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","article-title":"Risk factors for opportunistic infections in patients with inflammatory bowel disease","volume":"134","author":"Toruner","year":"2008","journal-title":"Gastroenterology"},{"key":"2022082312072164400_CIT0005","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1016\/0016-5085(91)90660-D","article-title":"The influence of zinc status and malnutrition on immunological function in Crohn\u2019s disease","volume":"100","author":"Ainley","year":"1991","journal-title":"Gastroenterology"},{"key":"2022082312072164400_CIT0006","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0140-6736(08)61199-X","article-title":"Common variable immunodeficiency: a new look at an old disease","volume":"372","author":"Park","year":"2008","journal-title":"Lancet"},{"key":"2022082312072164400_CIT0007","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1056\/NEJMcp051203","article-title":"Clinical practice. Management of newly diagnosed HIV infection","volume":"353","author":"Hammer","year":"2005","journal-title":"N Engl J Med"},{"key":"2022082312072164400_CIT0008","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/art.10529","article-title":"Predictors of infection in rheumatoid arthritis","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2022082312072164400_CIT0009","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/ajg.2012.218","article-title":"Serious infection and mortality in patients with Crohn\u2019s disease: more than 5 years of follow-up in the TREAT\u2122 registry","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"2022082312072164400_CIT0010","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cgh.2010.09.026","article-title":"Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease","volume":"9","author":"Cottone","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0011","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00535-012-0686-9","article-title":"A prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammatory bowel disease","volume":"48","author":"Naganuma","year":"2013","journal-title":"J Gastroenterol"},{"key":"2022082312072164400_CIT0012","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1038\/ajg.2016.433","article-title":"Crohn\u2019s disease activity and concomitant immunosuppressants affect the risk of serious and opportunistic infections in patients treated with adalimumab","volume":"111","author":"Osterman","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2022082312072164400_CIT0013","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.crohns.2012.02.015","article-title":"Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases","volume":"7","author":"Ananthakrishnan","year":"2013","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0014","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00384-019-03501-0","article-title":"Clinical assessment of risk factors for infection in inflammatory bowel disease patients","volume":"35","author":"Tosca","year":"2020","journal-title":"Int J Colorectal Dis"},{"key":"2022082312072164400_CIT0015","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12876-017-0602-0","article-title":"Inflammatory Bowel Disease [IBD] pharmacotherapy and the risk of serious infection: a systematic review and network meta-analysis","volume":"17","author":"Wheat","year":"2017","journal-title":"BMC Gastroenterol"},{"key":"2022082312072164400_CIT0016","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"2022082312072164400_CIT0017","first-page":"680","article-title":"Five-year safety data from ENCORE, a European Observational Safety Registry for adults with Crohn\u2019s disease treated with infliximab [Remicade\u00ae] or conventional therapy","volume":"11","author":"D\u2019Haens","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0018","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","article-title":"Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases","volume":"155","author":"Kirchgesner","year":"2018","journal-title":"Gastroenterology"},{"key":"2022082312072164400_CIT0019","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","article-title":"The safety profile of infliximab in patients with Crohn\u2019s disease: the Mayo clinic experience in 500 patients","volume":"126","author":"Colombel","year":"2004","journal-title":"Gastroenterology"},{"key":"2022082312072164400_CIT0020","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cgh.2019.02.044","article-title":"Comparative risk of serious infections with biologic and\/or immunosuppressive therapy in patients with inflammatory bowel diseases: a systematic review and meta-analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0021","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1093\/ecco-jcc\/jjz013","article-title":"Relevant infections in inflammatory bowel disease, and their relationship with immunosuppressive therapy and their effects on disease mortality","volume":"13","author":"Zabana","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0022","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"2022082312072164400_CIT0023","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/apt.14075","article-title":"Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease","volume":"46","author":"Bye","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2022082312072164400_CIT0024","doi-asserted-by":"crossref","first-page":"PE84","DOI":"10.1016\/S2665-9913(19)30137-7","article-title":"Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study","volume":"2","author":"Pawar","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2022082312072164400_CIT0025","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/annrheumdis-2019-216102","article-title":"Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis","volume":"79","author":"Li","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022082312072164400_CIT0026","first-page":"w14159","article-title":"Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases","volume":"145","author":"B\u00fchler","year":"2015","journal-title":"Swiss Med Wkly"},{"key":"2022082312072164400_CIT0027","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1053\/j.gastro.2008.07.081","article-title":"Oral budesonide for maintenance treatment of collagenous colitis: a randomised, double-blind, placebo-controlled trial","volume":"135","author":"Miehlke","year":"2008","journal-title":"Gastroenterology"},{"key":"2022082312072164400_CIT0028","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/gutjnl-2014-308363","article-title":"Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial","volume":"65","author":"M\u00fcnch","year":"2016","journal-title":"Gut"},{"key":"2022082312072164400_CIT0029","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1136\/ard.2010.144741","article-title":"The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study","volume":"70","author":"Dixon","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2022082312072164400_CIT0030","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.crohns.2013.08.017","article-title":"Prevalence and factors related to hepatitis B and C infection in inflammatory bowel disease patients in China: a retrospective study","volume":"8","author":"Huang","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0031","doi-asserted-by":"crossref","first-page":"97","DOI":"10.5217\/ir.2017.15.1.97","article-title":"Prevalence of hepatitis B, hepatitis C and human immunodeficiency viral infections in patients with inflammatory bowel disease in north India","volume":"15","author":"Harsh","year":"2017","journal-title":"Intest Res"},{"key":"2022082312072164400_CIT0032","first-page":"735","article-title":"Hepatitis A virus","volume-title":"Fields Virology","author":"Hollinger","year":"1996","edition":"3"},{"key":"2022082312072164400_CIT0033","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/MCG.0000000000000758","article-title":"Corticosteroids and thiopurines but not tumor necrosis factor antagonists are associated with cytomegalovirus reactivation in inflammatory bowel disease. A systematic review and meta-analysis","volume":"51","author":"Shukla","year":"2017","journal-title":"J Clin Gastroenterol"},{"key":"2022082312072164400_CIT0034","article-title":"CMV infection in pediatric severe ulcerative colitis \u2013 a multicenter study from the Pediatric Porto Group of ESPGHAN","author":"Cohen","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"2022082312072164400_CIT0035","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1097\/MIB.0b013e318281325e","article-title":"Risk factors for lymphoma in patients with inflammatory bowel disease: a case-control study","volume":"19","author":"Afif","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0036","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"key":"2022082312072164400_CIT0037","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/MIB.0000000000000338","article-title":"Are patients with inflammatory bowel disease on chronic immunosuppressive therapy at increased risk of cervical high-grade dysplasia\/cancer? A meta-analysis","volume":"21","author":"Allegretti","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0038","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10096-019-03706-9","article-title":"Increased risk of herpes zoster infection in patients with inflammatory bowel disease: a meta-analysis of cohort studies","volume":"39","author":"Ning","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2022082312072164400_CIT0039","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.cgh.2018.11.035","article-title":"Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials","volume":"17","author":"Sandborn","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0040","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2020.01.001","article-title":"Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis","author":"Olivera","year":"2020","journal-title":"Gastroenterology"},{"key":"2022082312072164400_CIT0041","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.tmaid.2006.04.004","article-title":"A review of the long-term protection after hepatitis A and B vaccination","volume":"5","author":"Van Damme","year":"2007","journal-title":"Travel Med Infect Dis"},{"key":"2022082312072164400_CIT0042","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/01.MIB.0000437736.91712.a1","article-title":"Efficacy of hepatitis A vaccination and factors impacting on seroconversion in patients with inflammatory bowel disease","volume":"20","author":"Park","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0043","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.dld.2017.09.002","article-title":"Screening, prophylaxis and counselling before the start of biological therapies: a practical approach focused on IBD patients","volume":"49","author":"Abreu","year":"2017","journal-title":"Dig Liver Dis"},{"key":"2022082312072164400_CIT0044","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/17474124.2019.1565993","article-title":"Updates on vaccinating the inflammatory bowel disease patient","volume":"13","author":"Zullow","year":"2019","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0045","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.15585\/mmwr.mm6743a5","article-title":"Update: recommendations of the advisory committee on immunization practices for use of hepatitis A vaccine for postexposure prophylaxis and for preexposure prophylaxis for International Travel","volume":"67","author":"Nelson","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022082312072164400_CIT0046","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/gut.2010.208413","article-title":"Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy","volume":"59","author":"Loras","year":"2010","journal-title":"Gut"},{"key":"2022082312072164400_CIT0047","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/ibd.22905","article-title":"Clinical courses of chronic hepatitis B virus infection and inflammatory bowel disease in patients with both diseases","volume":"18","author":"Park","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0048","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/MPG.0000000000001580","article-title":"Incidence of low seroimmunity to hepatitis B virus in children with inflammatory bowel disease","volume":"65","author":"Watts","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2022082312072164400_CIT0049","doi-asserted-by":"crossref","first-page":"7644","DOI":"10.3748\/wjg.v23.i42.7644","article-title":"Vaccinations in immunosuppressive-dependent pediatric inflammatory bowel disease","volume":"23","author":"Nguyen","year":"2017","journal-title":"World J Gastroenterol"},{"key":"2022082312072164400_CIT0050","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1016\/j.vaccine.2017.03.080","article-title":"Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: a systematic review and meta-analysis","volume":"35","author":"Jiang","year":"2017","journal-title":"Vaccine"},{"key":"2022082312072164400_CIT0051","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.crohns.2014.06.009","article-title":"Impact of surveillance of hepatitis B and hepatitis C in patients with inflammatory bowel disease under anti-TNF therapies: multicentre prospective observational study [REPENTINA 3]","volume":"8","author":"Loras","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0052","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1007\/s10620-019-05595-6","article-title":"Improved antibody response to three additional hepatitis B vaccine doses following primary vaccination failure in patients with inflammatory bowel disease","volume":"64","author":"Pratt","year":"2019","journal-title":"Dig Dis Sci"},{"key":"2022082312072164400_CIT0053","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/hep.27609","article-title":"Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?","volume":"61","author":"Di Bisceglie","year":"2015","journal-title":"Hepatology"},{"key":"2022082312072164400_CIT0054","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/j.cgh.2018.04.033","article-title":"Incidence of Hepatitis B virus reactivation and hepatotoxicity in patients receiving long-term treatment with tumor necrosis factor antagonists","volume":"16","author":"Morisco","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0055","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/MD.0b013e3182380a76","article-title":"Hepatitis B virus [HBV] reactivation in patients receiving tumor necrosis factor [TNF]-targeted therapy: analysis of 257 cases","volume":"90","author":"P\u00e9rez-Alvarez","year":"2011","journal-title":"Medicine"},{"key":"2022082312072164400_CIT0056","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/gut.2004.040675","article-title":"Chronic hepatitis B reactivation following infliximab therapy in Crohn\u2019s disease patients: need for primary prophylaxis","volume":"53","author":"Esteve","year":"2004","journal-title":"Gut"},{"key":"2022082312072164400_CIT0057","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(80)90442-0","article-title":"Serum levels of hepatitis B surface and core antigens during immunosuppressive treatment of HBsAg-positive chronic active hepatitis","volume":"2","author":"Sagnelli","year":"1980","journal-title":"Lancet"},{"key":"2022082312072164400_CIT0058","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017, Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"J Hepatol"},{"key":"2022082312072164400_CIT0059","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s10620-018-5042-3","article-title":"Hepatitis B virus screening and reactivation in a national VA cohort of patients with inflammatory bowel disease treated with tumor necrosis factor antagonists","volume":"63","year":"2018","journal-title":"Dig Dis Sci"},{"key":"2022082312072164400_CIT0060","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ad.2017.07.011","article-title":"Risk of hepatitis B virus reactivation in patients treated with anti-TNF agents for immune-mediated inflammatory diseases","volume":"109","author":"Pereira","year":"2018","journal-title":"Actas Dermosi\ufb01liogr"},{"key":"2022082312072164400_CIT0061","doi-asserted-by":"crossref","first-page":"ofv091","DOI":"10.1093\/ofid\/ofv091","article-title":"Durable sustained virologic response after oral directly acting antiviral therapy despite immunosuppressive treatment","volume":"2","author":"Hahn","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"2022082312072164400_CIT0062","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12876-016-0480-x","article-title":"Successful sofosbuvir treatment with ribavirin dose reduction for chronic hepatitis C virus genotype 2 infection in a patient with ulcerative colitis: a case report","volume":"16","author":"Ohta","year":"2016","journal-title":"BMC Gastroenterol"},{"key":"2022082312072164400_CIT0063","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/jvh.12768","article-title":"Successful treatment of chronic hepatitis C with ground ledipasvir\/sofosbuvir in a patient with Crohn\u2019s disease and short bowel syndrome","volume":"25","author":"von Felden","year":"2018","journal-title":"J Viral Hepat"},{"key":"2022082312072164400_CIT0064","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s15010-016-0915-x","article-title":"Colitis during new direct-acting antiviral agents [DAAs] therapy with sofosbuvir, simeprevir and ribavirin for genotype 1b hepatitis C","volume":"44","author":"Izzo","year":"2016","journal-title":"Infection"},{"key":"2022082312072164400_CIT0065","doi-asserted-by":"crossref","first-page":"42","DOI":"10.14309\/crj.2015.96","article-title":"Colitis following initiation of sofosbuvir and simeprevir for genotype 1 hepatitis C","volume":"3","author":"Sarkar","year":"2015","journal-title":"ACG Case Rep J"},{"key":"2022082312072164400_CIT0066","doi-asserted-by":"crossref","first-page":"7030","DOI":"10.3748\/wjg.v22.i31.7030","article-title":"Hepatitis E: discovery, global impact, control and cure","volume":"22","author":"Khuroo","year":"2016","journal-title":"World J Gastroenterol"},{"key":"2022082312072164400_CIT0067","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.vaccine.2015.07.056","article-title":"Hepatitis E vaccine: WHO position paper, May 2015 - recommendations","volume":"34","author":"World Health Organization","year":"2016","journal-title":"Vaccine"},{"key":"2022082312072164400_CIT0068","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.jhep.2018.03.005","article-title":"EASL clinical practice guidelines on hepatitis E virus infection","volume":"68","year":"2018","journal-title":"J Hepatol"},{"key":"2022082312072164400_CIT0069","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa0706992","article-title":"Hepatitis E virus and chronic hepatitis in organ-transplant recipients","volume":"358","author":"Kamar","year":"2008","journal-title":"N Engl J Med"},{"key":"2022082312072164400_CIT0070","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.gastrohep.2015.06.004","article-title":"Hepatitis E seroprevalence in inflammatory bowel disease","volume":"39","author":"Senosiaina","year":"2016","journal-title":"Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0071","first-page":"S1542-3565(20)31719-5","article-title":"Impact of HIV infection on the course of inflammatory bowel disease and drug safety profile: a multicenter GETAID study","author":"Guillo","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0072","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/QAD.0000000000000121","article-title":"Azathioprine can be safely used in HIV-infected individuals","volume":"28","author":"Chamberlain","year":"2014","journal-title":"AIDS"},{"key":"2022082312072164400_CIT0073","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.jaad.2015.11.043","article-title":"Use of tumor necrosis factor [TNF] inhibitors in patients with HIV\/AIDS","volume":"74","author":"Gallitano","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2022082312072164400_CIT0074","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/0956462416675109","article-title":"Systematic review of the efficacy and safety of biological therapy for inflammatory conditions in HIV-infected individuals","volume":"28","author":"Fink","year":"2017","journal-title":"Int J STD AIDS"},{"key":"2022082312072164400_CIT0075","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1126\/science.aag1276","article-title":"Sustained virologic control in SIV+ macaques after antiretroviral and \u03b14\u03b27 antibody therapy","volume":"354","author":"Byrareddy","year":"2016","journal-title":"Science"},{"key":"2022082312072164400_CIT0076","doi-asserted-by":"crossref","first-page":"e00056","DOI":"10.14309\/crj.0000000000000056","article-title":"New diagnosis of acquired immunodeficiency syndrome in a patient with Crohn\u2019s disease","volume":"6","author":"Aharoni Golan","year":"2019","journal-title":"ACG Case Rep J"},{"key":"2022082312072164400_CIT0077","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jaad.2009.03.047","article-title":"Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation","volume":"62","author":"Menon","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"2022082312072164400_CIT0078","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1001\/archderm.1987.01660360050012","article-title":"Acquired immunodeficiency syndrome-associated psoriasis and Reiter\u2019s syndrome","volume":"123","author":"Duvic","year":"1987","journal-title":"Arch Dermatol"},{"key":"2022082312072164400_CIT0079","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jaad.2007.06.027","article-title":"Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management","volume":"57","author":"Fatahzadeh","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"2022082312072164400_CIT0080","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(07)61908-4","article-title":"Genital herpes","volume":"370","author":"Gupta","year":"2007","journal-title":"Lancet"},{"key":"2022082312072164400_CIT0081","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/j.1365-2036.2009.03973.x","article-title":"Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine","volume":"29","author":"Seksik","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"2022082312072164400_CIT0082","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1086\/605498","article-title":"Herpes simplex encephalitis during treatment with tumor necrosis factor-alpha inhibitors","volume":"49","author":"Bradford","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2022082312072164400_CIT0083","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/ajg.2009.544","article-title":"Herpes simplex virus meningoencephalitis in a patient with Crohn\u2019s disease on azathioprine therapy","volume":"105","author":"Robineau","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"2022082312072164400_CIT0084","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/archneur.65.5.596","article-title":"Neurological complications of herpes simplex virus type 2 infection","volume":"65","author":"Berger","year":"2008","journal-title":"Arch Neurol"},{"key":"2022082312072164400_CIT0085","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1053\/srin.2002.33447","article-title":"Pneumonia caused by herpesviruses in recipients of hematopoietic cell transplants","volume":"17","author":"Taplitz","year":"2002","journal-title":"Semin Respir Infect"},{"key":"2022082312072164400_CIT0086","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1365-2036.2009.04112.x","article-title":"Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease","volume":"31","author":"Shale","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"2022082312072164400_CIT0087","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.crohns.2007.06.004","article-title":"Herpes simplex virus colitis complicating ulcerative colitis: a case report and brief review on superinfections","volume":"1","author":"Schunter","year":"2007","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0088","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1365-2559.2006.02460.x","article-title":"Herpes simplex virus colitis in ulcerative colitis, simulating malignancy","volume":"49","author":"Blaszyk","year":"2006","journal-title":"Histopathology"},{"key":"2022082312072164400_CIT0089","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/QCO.0b013e3282f3d9d3","article-title":"Treatment to prevent recurrent genital herpes","volume":"21","author":"Martinez","year":"2008","journal-title":"Curr Opin Infect Dis"},{"key":"2022082312072164400_CIT0090","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/ibd\/izy249","article-title":"Herpes zoster infection and herpes zoster vaccination in a population-based sample of persons with IBD: is there still an unmet need?","volume":"25","author":"Nugent","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0091","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.cgh.2018.10.016","article-title":"Efficacy of live attenuated herpes zoster vaccine in patients with inflammatory bowel diseases","volume":"17","author":"Khan","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0092","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/apt.14257","article-title":"Safety of herpes zoster vaccination among inflammatory bowel disease patients being treated with anti-TNF medications","volume":"46","author":"Khan","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2022082312072164400_CIT0093","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1097\/MIB.0000000000000743","article-title":"Herpes zoster vaccine response in inflammatory bowel disease patients on low-dose immunosuppression","volume":"22","author":"Wasan","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0094","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/acr.24010","article-title":"Live zoster vaccine in patients with rheumatoid arthritis treated with tofacitinib with or without methotrexate, or adalimumab with methotrexate: a post hoc analysis of data from a phase IIIb\/IV randomised study","volume":"72","author":"Calabrese","year":"2020","journal-title":"Arthritis Care Res"},{"key":"2022082312072164400_CIT0095","doi-asserted-by":"crossref","first-page":"e034886","DOI":"10.1136\/bmjopen-2019-034886","article-title":"Safety of inadvertent administration of live zoster vaccine to immunosuppressed individuals in a UK-based observational cohort analysis","volume":"10","author":"Grint","year":"2020","journal-title":"BMJ Open"},{"key":"2022082312072164400_CIT0096","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"2022082312072164400_CIT0097","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1093\/rheumatology\/keaa424","article-title":"Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomised trials","volume":"60","author":"Dagnew","year":"2021","journal-title":"Rheumatology"},{"key":"2022082312072164400_CIT0098","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/S0140-6736(18)30631-7","article-title":"Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Winston","year":"2018","journal-title":"Lancet"},{"key":"2022082312072164400_CIT0099","article-title":"Effectiveness of recombinant zoster vaccine [RZV] in immunosuppressed patients with inflammatory bowel disease: a population based analysis","author":"Kochhar","year":"2000"},{"key":"2022082312072164400_CIT0100","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1093\/ibd\/izy131","article-title":"Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib","volume":"24","author":"Winthrop","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0101"},{"key":"2022082312072164400_CIT0102","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/ajg.2016.537","article-title":"ACG clinical guideline: preventive care in inflammatory bowel disease","volume":"112","author":"Farraye","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"2022082312072164400_CIT0103","doi-asserted-by":"crossref","first-page":"E50","DOI":"10.1097\/MIB.0000000000001239","article-title":"Caution when assessing immunity to varicella through antibody testing in patients with inflammatory bowel disease","volume":"23","author":"Caldera","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0104","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1093\/cid\/cit684","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2022082312072164400_CIT0105","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1097\/MIB.0000000000000958","article-title":"Toward an algorithm for the diagnosis and management of CMV in patients with colitis","volume":"22","author":"Beswick","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0106","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/INF.0000000000001724","article-title":"Cytomegalovirus infection in pediatric severe ulcerative colitis - a multicenter study from the pediatric inflammatory bowel disease Porto group of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition","volume":"37","author":"Cohen","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"2022082312072164400_CIT0107","doi-asserted-by":"crossref","first-page":"643","DOI":"10.5009\/gnl13427","article-title":"Long-term outcomes of cytomegalovirus reactivation in patients with moderate to severe ulcerative colitis: a multicenter study","volume":"8","author":"Kim","year":"2014","journal-title":"Gut Liver"},{"key":"2022082312072164400_CIT0108","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00384-018-3210-8","article-title":"The detection of the cytomegalovirus DNA in the colonic mucosa of patients with ulcerative colitis is associated with increased long-term risk of proctocolectomy: results from an outpatient IBD clinic","volume":"34","author":"Schenk","year":"2019","journal-title":"Int J Colorectal Dis"},{"key":"2022082312072164400_CIT0109","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1097\/MIB.0000000000000675","article-title":"Risk factors and clinical outcomes associated with cytomegalovirus colitis in patients with acute severe ulcerative colitis","volume":"22","author":"Lee","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0110","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jcv.2015.03.009","article-title":"Toxic megacolon and human Cytomegalovirus in a series of severe ulcerative colitis patients","volume":"66","author":"Criscuoli","year":"2015","journal-title":"J Clin Virol"},{"key":"2022082312072164400_CIT0111","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/MEG.0000000000000028","article-title":"What are the factors that affect hospitalization and surgery for aggravation of ulcerative colitis?","volume":"26","author":"Matsumoto","year":"2014","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0112","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1080\/00365521.2019.1646798","article-title":"True cytomegalovirus colitis is a poor prognostic indicator in patients with ulcerative colitis flares: the 10-year experience of an academic referral inflammatory bowel disease center","volume":"54","author":"Oh","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"2022082312072164400_CIT0113","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.3892\/etm.2016.3763","article-title":"Effects of cytomegalovirus infection on the prognosis of inflammatory bowel disease patients","volume":"12","author":"Zhang","year":"2016","journal-title":"Exp Ther Med"},{"key":"2022082312072164400_CIT0114","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.cgh.2014.05.026","article-title":"A model for identifying cytomegalovirus in patients with inflammatory bowel disease","volume":"13","author":"McCurdy","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0115","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jcv.2018.06.002","article-title":"Novel score predicts risk for cytomegalovirus infection in ulcerative colitis","volume":"105","author":"Nowacki","year":"2018","journal-title":"J Clin Virol"},{"key":"2022082312072164400_CIT0116","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3164\/jcbn.18-14","article-title":"Cytomegalovirus infection in ulcerative colitis assessed by quantitative polymerase chain reaction: risk factors and effects of immunosuppressants","volume":"63","author":"Henmi","year":"2018","journal-title":"J Clin Biochem Nutr"},{"key":"2022082312072164400_CIT0117","first-page":"81","article-title":"Polymerase chain reaction for detection of mucosal cytomegalovirus infection in patients with acute ulcerative colitis","volume":"32","author":"Tun","year":"2019","journal-title":"Ann Gastroenterol"},{"key":"2022082312072164400_CIT0118","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s11845-018-1752-y","article-title":"Cytomegalovirus infection and steroid-refractory inflammatory bowel disease: possible relationship from an updated meta-analysis","volume":"187","author":"Liu","year":"2018","journal-title":"Ir J Med Sci"},{"key":"2022082312072164400_CIT0119","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2147\/IDR.S149784","article-title":"Is cytomegalovirus infection related to inflammatory bowel disease, especially steroid-resistant inflammatory bowel disease? A meta-analysis","volume":"10","author":"Lv","year":"2017","journal-title":"Infect Drug Resist"},{"key":"2022082312072164400_CIT0120","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1007\/s10620-015-3733-6","article-title":"Relationship between cytomegalovirus infection and steroid resistance in inflammatory bowel disease: a meta-analysis","volume":"60","author":"Wu","year":"2015","journal-title":"Dig Dis Sci"},{"key":"2022082312072164400_CIT0121","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/MIB.0000000000001073","article-title":"Diagnostic accuracy of blood-based tests and histopathology for cytomegalovirus reactivation in inflammatory bowel disease: a systematic review and meta-analysis","volume":"23","author":"Tandon","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0122","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/TP.0b013e31829df29d","article-title":"Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"96","author":"Kotton","year":"2013","journal-title":"Transplantation"},{"key":"2022082312072164400_CIT0123","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/bjh.12363","article-title":"Management of cytomegalovirus infection in haemopoietic stem cell transplantation","volume":"162","author":"Emery","year":"2013","journal-title":"Br J Haematol"},{"key":"2022082312072164400_CIT0124","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.crohns.2013.12.014","article-title":"Clinical utility of cytomegalovirus antigenaemia assay and blood cytomegalovirus DNA PCR for cytomegaloviral colitis patients with moderate to severe ulcerative colitis","volume":"8","author":"Kim","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0125","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1038\/ajg.2011.202","article-title":"Cytomegalovirus load in inflamed intestinal tissue is predictive of resistance to immunosuppressive therapy in ulcerative colitis","volume":"106","author":"Roblin","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2022082312072164400_CIT0126","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00428-015-1741-8","article-title":"Diagnosing cytomegalovirus in patients with inflammatory bowel disease \u2013 by immunohistochemistry or polymerase chain reaction?","volume":"466","author":"Zidar","year":"2015","journal-title":"Virchows Arch"},{"key":"2022082312072164400_CIT0127","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1097\/MIB.0000000000000556","article-title":"Detection of cytomegalovirus in patients with inflammatory bowel disease: where to biopsy and how many biopsies?","volume":"21","author":"McCurdy","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0128","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/ibd\/izy045","article-title":"CMV disease in IBD: comparison of diagnostic tests and correlation with disease outcome","volume":"24","author":"Johnson","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0129","first-page":"14","article-title":"Ulcerative colitis and cytomegalovirus infection: from A to Z","volume":"8","author":"Mourad","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0130","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3748\/wjg.v20.i2.509","article-title":"Long-term follow-up of ulcerative colitis patients treated on the basis of their cytomegalovirus antigen status","volume":"20","author":"Inokuchi","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2022082312072164400_CIT0131","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1093\/ecco-jcc\/jjz033","article-title":"Resolution of CMV infection in the bowel on vedolizumab therapy","volume":"13","author":"Rawa-Go\u0142\u0119biewska","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0132","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1093\/ecco-jcc\/jjz108","article-title":"Comment on: \u2018Resolution of CMV infection in the bowel on vedolizumab therapy\u2019","volume":"14","author":"Hommel","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0133","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1097\/MEG.0000000000000716","article-title":"Cytomegalovirus disease in inflammatory bowel disease: epidemiology and disease characteristics in a large single-centre experience","volume":"28","author":"Bont\u00e0","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0134","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.3748\/wjg.v21.i6.1915","article-title":"Human cytomegalovirus and Epstein-Barr virus infection in inflammatory bowel disease: need for mucosal viral load measurement","volume":"21","author":"Ciccocioppo","year":"2015","journal-title":"World J Gastroenterol"},{"key":"2022082312072164400_CIT0135","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/ecco-jcc\/jjy173","article-title":"Prognostic value of the burden of cytomegalovirus colonic reactivation evaluated by immunohistochemical staining in patients with active ulcerative colitis","volume":"13","author":"Clos-Parals","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0136","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/apt.12650","article-title":"The impact of cytomegalovirus reactivation and its treatment on the course of inflammatory bowel disease","volume":"39","author":"Delvincourt","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"2022082312072164400_CIT0137","doi-asserted-by":"crossref","first-page":"e0133102","DOI":"10.1371\/journal.pone.0133102","article-title":"Cytomegalovirus infection in inflammatory bowel disease is not associated with worsening of intestinal inflammatory activity","volume":"10","author":"do Carmo","year":"2015","journal-title":"PLoS One"},{"key":"2022082312072164400_CIT0138","doi-asserted-by":"crossref","first-page":"301","DOI":"10.4253\/wjge.v8.i6.301","article-title":"Characteristic endoscopic findings and risk factors for cytomegalovirus-associated colitis in patients with active ulcerative colitis","volume":"8","author":"Hirayama","year":"2016","journal-title":"World J Gastrointest Endosc"},{"key":"2022082312072164400_CIT0139","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/MIB.0000000000001160","article-title":"Impact of infliximab and cyclosporine on the risk of colectomy in hospitalized patients with ulcerative colitis complicated by cytomegalovirus- a multicenter retrospective study","volume":"23","author":"Kopylov","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0140","first-page":"858","article-title":"Steroid-refractory inflammatory bowel disease is a risk factor for CMV infection","volume":"20","author":"Ormeci","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2022082312072164400_CIT0141","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1159\/000479865","article-title":"Diagnosis of cytomegalovirus infection during exacerbation of ulcerative colitis","volume":"96","author":"Levin","year":"2017","journal-title":"Digestion"},{"key":"2022082312072164400_CIT0142","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.gastrohep.2017.06.008","article-title":"Cytomegalovirus primoinfection in inflammatory bowel disease","volume":"41","author":"Torres","year":"2018","journal-title":"Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0143","doi-asserted-by":"crossref","first-page":"6156581","DOI":"10.1155\/2019\/6156581","article-title":"A practical review of cytomegalovirus in gastroenterology and hepatology","volume":"2019","author":"Fakhreddine","year":"2019","journal-title":"Gastroenterol Res Pract"},{"key":"2022082312072164400_CIT0144","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.3748\/wjg.v20.i10.2695","article-title":"Antiviral therapy in cytomegalovirus-positive ulcerative colitis: a systematic review and meta-analysis","volume":"20","author":"Kopylov","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2022082312072164400_CIT0145","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1097\/MIB.0000000000000489","article-title":"Antiviral therapy in steroid-refractory ulcerative colitis with cytomegalovirus: systematic review and meta-analysis","volume":"21","author":"Shukla","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0146","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.cgh.2014.09.042","article-title":"Effects of antiviral therapy for patients with inflammatory bowel disease and a positive intestinal biopsy for cytomegalovirus","volume":"13","author":"Jones","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0147","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/ecco-jcc\/jjw071","article-title":"Cytomegalovirus infection in ulcerative colitis is related to severe inflammation and a high count of cytomegalovirus-positive cells in biopsy is a risk factor for colectomy","volume":"10","author":"Zago\u0301rowicz","year":"2016","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0148","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/apt.14933","article-title":"Impact of Epstein-Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease","volume":"48","author":"de Francisco","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2022082312072164400_CIT0149","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/MPG.0000000000001077","article-title":"EBV status and thiopurine use in pediatric IBD","volume":"62","author":"Gordon","year":"2016","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2022082312072164400_CIT0150","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1473-3099(03)00543-7","article-title":"Epstein-Barr virus\u2014recent advances","volume":"3","author":"Macsween","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"2022082312072164400_CIT0151","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaci.2005.05.038","article-title":"EBV the prototypical human tumor virus\u2014just how bad is it?","volume":"116","author":"Thorley-Lawson","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"2022082312072164400_CIT0152","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/s12879-019-4022-3","article-title":"A nearly fatal primary Epstein-Barr virus infection associated with low NK-cell counts in a patient receiving azathioprine: a case report and review of literature","volume":"19","author":"Honkila","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2022082312072164400_CIT0153","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-218578","article-title":"Crohn\u2019s disease complicated by Epstein-Barr virus-driven haemophagocytic lymphohistiocytosis successfully treated with rituximab","author":"Thompson","year":"2017","journal-title":"BMJ Case Rep"},{"key":"2022082312072164400_CIT0154","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00384-019-03257-7","article-title":"Clinical and endoscopic complications of Epstein-Barr virus in inflammatory bowel disease: an illustrative case series","volume":"34","author":"Goetgebuer","year":"2019","journal-title":"Int J Colorectal Dis"},{"key":"2022082312072164400_CIT0155","doi-asserted-by":"crossref","first-page":"306","DOI":"10.4240\/wjgs.v5.i11.306","article-title":"Hemophagocytic lymphohistiocytosis caused by primary Epstein-Barr virus in patient with Crohn\u2019s disease","volume":"5","author":"Virdis","year":"2013","journal-title":"World J Gastrointest Surg"},{"key":"2022082312072164400_CIT0156","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1097\/MIB.0b013e318281f31c","article-title":"Epstein-Barr virus in inflammatory bowel disease - correlation with different therapeutic regimens","volume":"19","author":"Magro","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0157","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/apt.12503","article-title":"Prevalence of Epstein-Barr Virus in a population of patients with inflammatory bowel disease: a prospective cohort study","volume":"38","author":"Linton","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"2022082312072164400_CIT0158","article-title":"Incidence, recurrence and survival post chemotherapy in renal transplant recipients with post transplant lymphoproliferative disorder: single center study","author":"Rathore","year":"2017","journal-title":"Am J Transplant"},{"key":"2022082312072164400_CIT0159","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1158\/1078-0432.CCR-0670-3","article-title":"Epstein-Barr virus and cancer","volume":"10","author":"Thompson","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2022082312072164400_CIT0160","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1053\/gast.2002.30328","article-title":"Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine","volume":"122","author":"Dayharsh","year":"2002","journal-title":"Gastroenterology"},{"key":"2022082312072164400_CIT0161","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/LGT.0b013e318187a7ee","article-title":"Hodgkin lymphoma presenting as a vulvar mass in a patient with Crohn disease: a case report and literature review","volume":"13","author":"Winnicki","year":"2009","journal-title":"J Low Genit Tract Dis"},{"key":"2022082312072164400_CIT0162","first-page":"33","article-title":"Epstein-Barr virus related lymphoma in inflammatory bowel disease","volume":"71","author":"Van Biervliet","year":"2008","journal-title":"Acta Gastroenterol Belg"},{"key":"2022082312072164400_CIT0163","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.3748\/wjg.v21.i19.6072","article-title":"Epstein Barr virus-positive mucocutaneous ulcer of the colon associated Hodgkin lymphoma in Crohn\u2019s disease","volume":"21","author":"Moran","year":"2015","journal-title":"World J Gastroenterol"},{"key":"2022082312072164400_CIT0164","first-page":"2014","article-title":"Primary CNS lymphoma in a patient treated with azathioprine","author":"Glesner","year":"2014","journal-title":"BMJ Case Rep"},{"key":"2022082312072164400_CIT0165","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/1752-1947-6-141","article-title":"Diffuse large B-cell lymphoma in an adolescent female presenting with Epstein-Barr virus-driven hemophagocytic lymphohistiocytosis: a case report","volume":"6","author":"Altaf","year":"2012","journal-title":"J Med Case Rep"},{"key":"2022082312072164400_CIT0166","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.clim.2013.07.004","article-title":"X-linked inhibitor of apoptosis [XIAP] deficiency: the spectrum of presenting manifestations beyond hemophagocytic lymphohistiocytosis","volume":"149","author":"Speckmann","year":"2013","journal-title":"Clin Immunol"},{"key":"2022082312072164400_CIT0167","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jpeds.2011.04.045","article-title":"Association of Crohn\u2019s disease, thiopurines, and primary Epstein-Barr virus infection with hemophagocytic lymphohistiocytosis","volume":"159","author":"Biank","year":"2011","journal-title":"J Pediatr"},{"key":"2022082312072164400_CIT0168","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1002\/lary.26009","article-title":"Head and neck Epstein-Barr virus mucocutaneous ulcer: case report and literature review","volume":"126","author":"Au","year":"2016","journal-title":"Laryngoscope"},{"key":"2022082312072164400_CIT0169","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/PAS.0b013e3181cf8622","article-title":"EBV positive mucocutaneous ulcer \u2013 a study of 26 cases associated with various sources of immunosuppression","volume":"34","author":"Dojcinov","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"2022082312072164400_CIT0170","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.dld.2017.03.011","article-title":"Epstein-Barr virus-positive mucocutaneous ulcer in Crohn\u2019s disease. A condition to consider in immunosuppressed IBD patients","volume":"49","author":"Juan","year":"2017","journal-title":"Dig Liver Dis"},{"key":"2022082312072164400_CIT0171","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.crohns.2014.08.010","article-title":"Azathioprine induced Epstein Barr virus-positive mucocutaneous ulcer arising in perianal fistula and abscess associated with Crohn\u2019s disease","volume":"8","author":"Matnani","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0172","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s12328-019-00952-4","article-title":"Immunomodulator-associated Epstein-Barr virus-positive mucocutaneous ulcer in a patient with refractory Crohn\u2019s disease","volume":"12","author":"Hamanaka","year":"2019","journal-title":"Clin J Gastroenterol"},{"key":"2022082312072164400_CIT0173","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/ibd\/izy243","article-title":"Increased risk of influenza and influenza-related complications among 140,480 patients with inflammatory bowel disease","volume":"25","author":"Tinsley","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0174","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.crohns.2012.06.019","article-title":"Incidence and characteristics of the 2009 influenza [H1N1] infections in inflammatory bowel disease patients","volume":"7","author":"Naganuma","year":"2013","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0175","doi-asserted-by":"crossref","first-page":"e1001053","DOI":"10.1371\/journal.pmed.1001053","article-title":"Risk factors for severe outcomes following 2009 influenza A [H1N1] infection: a global pooled analysis","volume":"8","author":"Van Kerkhove","year":"2011","journal-title":"PLoS Med"},{"key":"2022082312072164400_CIT0176","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1365-2036.2010.04558.x","article-title":"Influenza A [H1N1]v infection in patients with inflammatory bowel disease: a case series","volume":"33","author":"Rahier","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"2022082312072164400_CIT0177","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6908a1","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on immunization practices - United States, 2020-21 influenza season","volume":"69","author":"Grohskopf","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"2022082312072164400_CIT0178","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1155\/2012\/158362","article-title":"An audit of influenza vaccination status in adults with inflammatory bowel disease","volume":"26","author":"Narula","year":"2012","journal-title":"Can J Gastroenterol"},{"key":"2022082312072164400_CIT0179","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1471-230X-11-87","article-title":"An Australian audit of vaccination status in children and adolescents with inflammatory bowel disease","volume":"11","author":"Crawford","year":"2011","journal-title":"BMC Gastroenterol"},{"key":"2022082312072164400_CIT0180","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/01.MIB.0000440816.76627.bf","article-title":"Utilization of influenza immunization in adults with Crohn\u2019s disease - a longitudinal, population-based study","volume":"20","author":"Boltin","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0181","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/MIB.0000000000001013","article-title":"Effects of education and information on vaccination behavior in patients with inflammatory bowel disease","volume":"23","author":"Coenen","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0182","first-page":"396","article-title":"Influenza and pneumococcal vaccination rates in patients with inflammatory bowel disease","volume":"11","author":"Reich","year":"2015","journal-title":"Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0183","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/apt.15057","article-title":"Vaccination for influenza and pneumococcus in patients with gastrointestinal cancer or inflammatory bowel disease: a prospective cohort study of methods for improving coverage","volume":"49","author":"Sitte","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2022082312072164400_CIT0184","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.crohns.2012.05.011","article-title":"Immune response to influenza A\/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-\u03b1 agents: effects of combined therapy with immunosuppressants","volume":"7","author":"Andrisani","year":"2013","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0185","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/gutjnl-2011-300256","article-title":"Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease","volume":"61","author":"Cullen","year":"2012","journal-title":"Gut"},{"key":"2022082312072164400_CIT0186","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/ibd.21706","article-title":"Immunogenicity and safety of influenza vaccination in children with inflammatory bowel disease","volume":"18","author":"deBruyn","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0187","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.crohns.2013.08.008","article-title":"Infliximab and\/or immunomodulators inhibit immune responses to trivalent influenza vaccination in adults with inflammatory bowel disease","volume":"8","author":"Hagihara","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0188","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.cgh.2007.02.035","article-title":"Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease","volume":"5","author":"Mamula","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0189","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/ajg.2008.120","article-title":"Immune response to influenza vaccine in children with inflammatory bowel disease","volume":"104","author":"Lu","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"2022082312072164400_CIT0190","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/MIB.0000000000000615","article-title":"Immunogenicity of influenza vaccine for patients with inflammatory bowel disease on maintenance infliximab therapy: a randomised trial","volume":"22","author":"deBruyn","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0191","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/ecco-jcc\/jjv152","article-title":"Immunogenicity and safety of influenza vaccine in inflammatory bowel disease patients treated or not with immunomodulators and\/or biologics: a 2-year prospective study","volume":"9","author":"Launay","year":"2015","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0192","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13075-019-1883-1","article-title":"Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy","volume":"21","author":"Winthrop","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2022082312072164400_CIT0193","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/annrheumdis-2014-207191","article-title":"The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2022082312072164400_CIT0194","first-page":"593","article-title":"Immunogenicity of high dose influenza vaccine for patients with inflammatory bowel disease on anti-TNF monotherapy: a randomized clinical trial","volume":"26","author":"Caldera","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0195","first-page":"898","article-title":"Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomized clinical trial","volume":"77","author":"Park","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2022082312072164400_CIT0196","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1007\/s00535-015-1042-7","article-title":"Booster influenza vaccination does not improve immune response in adult inflammatory bowel disease patients treated with immunosuppressives: a randomized controlled trial","volume":"50","author":"Matsumoto","year":"2015","journal-title":"J Gastroenterol"},{"key":"2022082312072164400_CIT0197","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/ibd\/izx101","article-title":"Immunogenicity of quadrivalent influenza vaccine for patients with inflammatory bowel disease undergoing immunosuppressive therapy","volume":"24","author":"Shirai","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0198","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1136\/gut.2010.233981","article-title":"H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy","volume":"60","author":"Rahier","year":"2011","journal-title":"Gut"},{"key":"2022082312072164400_CIT0199","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1002\/ibd.22950","article-title":"Varicella zoster virus infection in inflammatory bowel disease","volume":"18","author":"Cullen","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1179547619858979","article-title":"Fulminant herpes simplex hepatitis secondary to adalimumab in Crohn\u2019s disease: a case report","volume":"12","author":"Goel","year":"2019","journal-title":"Clin Med Insights Case Rep"},{"key":"2022082312072164400_CIT0201","doi-asserted-by":"crossref","first-page":"2132056","DOI":"10.1155\/2016\/2132056","article-title":"Fulminant hepatic failure in a patient with Crohn\u2019s disease on infliximab possibly related to reactivation of herpes simplex virus 2 infection","volume":"2016","author":"Golds","year":"2016","journal-title":"Case Reports Hepatol"},{"key":"2022082312072164400_CIT0202","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/ecco-jcc\/jjv149","article-title":"Herpes simplex virus sepsis in a young woman with Crohn\u2019s disease","volume":"9","author":"Haag","year":"2015","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0203","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.cgh.2017.12.052","article-title":"Overall and comparative risk of herpes zoster with pharmacotherapy for inflammatory bowel diseases: a nationwide cohort study","volume":"16","author":"Khan","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0204","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3390\/microorganisms8020276","article-title":"Measles: an overview of a re-emerging disease in children and immunocompromised patients","volume":"8","author":"Misin","year":"2020","journal-title":"Microorganisms"},{"key":"2022082312072164400_CIT0205","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.14309\/ajg.0000000000000396","article-title":"Managing immunosuppressed patients with inflammatory bowel disease during a measles outbreak","volume":"114","author":"Cohen","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"2022082312072164400_CIT0206","first-page":"103","article-title":"Measles virus and dendritic cell functions: how specific response cohabits with immunosuppression","volume":"276","author":"Servet-Delprat","year":"2003","journal-title":"Curr Top Microbiol Immunol"},{"key":"2022082312072164400_CIT0207","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciy866","article-title":"Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza","volume":"68","author":"Uyeki","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2022082312072164400_CIT0208","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1038\/ajg.2009.322","article-title":"Adverse events associated with common therapy regimens for moderate-to-severe Crohn\u2019s disease","volume":"104","author":"Marehbian","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"2022082312072164400_CIT0209","volume-title":"Sexually Transmitted Diseases Treatment Guidelines","author":"Centers for Disease Control and Prevention","year":"2015"},{"key":"2022082312072164400_CIT0210","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/infdis\/163.5.1001","article-title":"Herpes simplex virus hepatitis after solid organ transplantation in adults","volume":"163","author":"Kusne","year":"1991","journal-title":"J Infect Dis"},{"key":"2022082312072164400_CIT0211","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1111\/ajt.14192","article-title":"Preventive strategies against cytomegalovirus and incidence of \u03b1-herpes virus infections in solid organ transplant recipients: a nationwide cohort study","volume":"17","author":"Martin-Gandul","year":"2017","journal-title":"Am J Transplant"},{"key":"2022082312072164400_CIT0212","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1056\/NEJM198112103052403","article-title":"Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions","volume":"305","author":"Siegal","year":"1981","journal-title":"N Engl J Med"},{"key":"2022082312072164400_CIT0213","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1086\/518938","article-title":"Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus [HSV] disease and drug-resistant HSV disease","volume":"196","author":"Erard","year":"2007","journal-title":"J Infect Dis"},{"key":"2022082312072164400_CIT0214","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jiac.2015.10.003","article-title":"Polish Consensus guidelines on the use of acyclovir in the treatment and prevention of VZV and HSV infections","volume":"22","author":"Szenborn","year":"2016","journal-title":"J Infect Chemother"},{"key":"2022082312072164400_CIT0215","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJMcp1302674","article-title":"Clinical practice: herpes zoster","volume":"369","author":"Cohen","year":"2013","journal-title":"N Engl J Med"},{"key":"2022082312072164400_CIT0216","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1097\/MIB.0000000000000902","article-title":"Management and prevention of herpes zoster in the immunocompromised inflammatory bowel disease patient: a clinical quandary","volume":"22","author":"C\u00f4t\u00e9-Daigneault","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0217","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1086\/510206","article-title":"Recommendations for the management of herpes zoster","volume":"44[Suppl 1]","author":"Dworkin","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2022082312072164400_CIT0218","first-page":"1","article-title":"Advisory Committee on Immunization Practices [ACIP], Centers for Disease Control and Prevention [CDC]. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices [ACIP]","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"2022082312072164400_CIT0219","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1093\/ibd\/izy150","article-title":"Herpes zoster in patients receiving JAK inhibitors for ulcerative colitis: mechanism, epidemiology, management, and prevention","volume":"24","author":"Colombel","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0220","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/gastro\/goy053","article-title":"High-risk human papilloma virus infection and cervical neoplasm in female inflammatory bowel disease patients: a cross-sectional study","volume":"7","author":"Li","year":"2019","journal-title":"Gastroenterol Rep"},{"key":"2022082312072164400_CIT0221","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cgh.2014.07.036","article-title":"Inflammatory bowel disease and cervical neoplasia: a population-based nationwide cohort study","volume":"13","author":"Rungoe","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0222","doi-asserted-by":"crossref","first-page":"E711","DOI":"10.1002\/ijc.29209","article-title":"Risk of cervical cancer in women with autoimmune diseases, in relation with their use of immunosuppressants and screening: population-based cohort study","volume":"136","author":"Dugu\u00e9","year":"2015","journal-title":"Int J Cancer"},{"key":"2022082312072164400_CIT0223","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/j.gastro.2008.10.021","article-title":"Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study","volume":"136","author":"Singh","year":"2009","journal-title":"Gastroenterology"},{"key":"2022082312072164400_CIT0224","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/apt.13215","article-title":"Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease","volume":"41","author":"Luthra","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"2022082312072164400_CIT0225","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol"},{"key":"2022082312072164400_CIT0226","first-page":"1","article-title":"Sexually transmitted diseases treatment guidelines, 2015. Centers for Disease Control and Prevention","volume":"64","author":"Workowski","year":"2015","journal-title":"MMWR Recomm Rep"},{"key":"2022082312072164400_CIT0227","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/LGT.0000000000000468","article-title":"Guidelines for cervical cancer screening in immunosuppressed women without HIV infection","volume":"23","author":"Moscicki","year":"2019","journal-title":"J Low Genit Tract Dis"},{"key":"2022082312072164400_CIT0228","doi-asserted-by":"crossref","first-page":"698","DOI":"10.15585\/mmwr.mm6832a3","article-title":"Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices","volume":"68","author":"Meites","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022082312072164400_CIT0229","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1097\/MIB.0b013e318281341b","article-title":"Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease","volume":"19","author":"Jacobson","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0230","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/annrheumdis-2012-201393","article-title":"Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study","volume":"72","author":"Mok","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2022082312072164400_CIT0231","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1016\/j.vaccine.2018.04.056","article-title":"Long-term immunogenicity of a quadrivalent human papillomavirus vaccine in systemic lupus erythematosus","volume":"36","author":"Mok","year":"2018","journal-title":"Vaccine"},{"key":"2022082312072164400_CIT0232","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1546-0096-11-29","article-title":"Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years","volume":"11","author":"Soybilgic","year":"2013","journal-title":"Pediatr Rheumatol Online J"},{"key":"2022082312072164400_CIT0233","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1136\/annrheumdis-2013-203429","article-title":"Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study","volume":"73","author":"Heijstek","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2022082312072164400_CIT0234","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1586\/14760584.2014.943195","article-title":"Immunogenicity, safety and tolerability of a bivalent human papillomavirus vaccine in adolescents with juvenile idiopathic arthritis","volume":"13","author":"Esposito","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"2022082312072164400_CIT0235","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/ecco-jcc\/jjz137","article-title":"The safety profile of vedolizumab in ulcerative colitis and Crohn\u2019s disease: 4 years of global post-marketing data","volume":"14","author":"Cohen","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0236","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/apt.15804","article-title":"2019 novel coronavirus disease [COVID-19] in patients with inflammatory bowel diseases","volume":"52","author":"Taxonera","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2022082312072164400_CIT0237","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.cgh.2020.04.071","article-title":"Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the Nancy and Milan cohorts","volume":"18","author":"Allocca","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0238","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S2468-1253(20)30121-7","article-title":"Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, China","volume":"5","author":"An","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0239","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/gutjnl-2020-322539","article-title":"Effect of IBD medications on COVID-19 outcomes: results from an international registry","volume":"70","author":"Ungaro","year":"2021","journal-title":"Gut"},{"key":"2022082312072164400_CIT0240","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1136\/gutjnl-2020-321411","article-title":"Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study","volume":"69","author":"Bezzio","year":"2020","journal-title":"Gut"},{"key":"2022082312072164400_CIT0241","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1136\/gutjnl-2020-321013","article-title":"Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection","volume":"69","author":"Lin","year":"2020","journal-title":"Gut"},{"key":"2022082312072164400_CIT0242","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/ecco-jcc\/jjaa160","article-title":"Inflammatory bowel disease management during the COVID-19 outbreak: the 10 do\u2019s and don\u2019ts from the ECCO-COVID taskforce","volume":"14","author":"Magro","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0243","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1053\/j.gastro.2020.04.043","article-title":"Characteristics and prognosis of patients with inflammatory bowel disease during the SARS-CoV-2 pandemic in the Basque Country [Spain]","volume":"159","author":"Rodr\u00edguez-Lago","year":"2020","journal-title":"Gastroenterology"},{"key":"2022082312072164400_CIT0244","first-page":"1769","article-title":"Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel","volume":"69","author":"Din","year":"2020","journal-title":"Gut"},{"key":"2022082312072164400_CIT0245","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41577-020-00434-6","article-title":"Immunological considerations for COVID-19 vaccine strategies","volume":"20","author":"Jeyanathan","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"2022082312072164400_CIT0246","volume-title":"Draft Landscape of COVID-19 Candidate Vaccines","author":"World Health Organization","year":"2020"},{"key":"2022082312072164400_CIT0247"},{"key":"2022082312072164400_CIT0248"},{"key":"2022082312072164400_CIT0249"},{"key":"2022082312072164400_CIT0250"},{"key":"2022082312072164400_CIT0251","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/gutjnl-2020-324000","article-title":"SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting","volume":"70","author":"Siegel","year":"2021","journal-title":"Gut"},{"key":"2022082312072164400_CIT0252","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S2468-1253(21)00024-8","article-title":"SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement","volume":"6","author":"Alexander","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0253","doi-asserted-by":"crossref","first-page":"e0189202","DOI":"10.1371\/journal.pone.0189202","article-title":"Immune-mediated inflammatory diseases differently affect IGRAs\u2019 accuracy for latent tuberculosis infection diagnosis in clinical practice","volume":"12","author":"Latorre","year":"2017","journal-title":"PLoS One"},{"key":"2022082312072164400_CIT0254","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/thoraxjnl-2015-207811","article-title":"Effect of immunosuppressive therapy on interferon \u03b3 release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis","volume":"71","author":"Wong","year":"2016","journal-title":"Thorax"},{"key":"2022082312072164400_CIT0255","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1097\/MIB.0000000000000147","article-title":"Performance of interferon-gamma release assay for tuberculosis screening in inflammatory bowel disease patients","volume":"20","author":"Wong","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0256","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.cgh.2016.04.039","article-title":"Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis","volume":"14","author":"Bonovas","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0257","first-page":"CD008794","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","volume":"2011","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"2022082312072164400_CIT0258","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3109\/07853890.2014.941919","article-title":"Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials","volume":"46","author":"Lorenzetti","year":"2014","journal-title":"Ann Med"},{"key":"2022082312072164400_CIT0259","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1093\/ibd\/izy153","article-title":"Low frequency of opportunistic infections in patients receiving vedolizumab in clinical trials and post-marketing setting","volume":"24","author":"Ng","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0260","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/j.1365-2133.2012.11142.x","article-title":"The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection","volume":"167","author":"Tsai","year":"2012","journal-title":"Br J Dermatol"},{"key":"2022082312072164400_CIT0261","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(17)32134-0","volume-title":"Comparison of rates of active tuberculosis infection in the phase 2 and 3 clinical trial programs for anti-IL12\/23 and anti-TNFS. In: Digestive Disease Week; May 6-9, 2017","author":"Loftus","year":""},{"key":"2022082312072164400_CIT0262","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","article-title":"Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2022082312072164400_CIT0263","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s10067-010-1380-z","article-title":"Methotrexate treatment in rheumatoid arthritis: management in clinical remission, common infection and tuberculosis. Results from a systematic literature review","volume":"29","author":"Bogas","year":"2010","journal-title":"Clin Rheumatol"},{"key":"2022082312072164400_CIT0264","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2012.12.966","article-title":"Association between traditional systemic antipsoriatic drugs and tuberculosis risk in patients with psoriasis with or without psoriatic arthritis: results of a nationwide cohort study from Taiwan","volume":"69","author":"Chen","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"2022082312072164400_CIT0265","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1111\/crj.12726","article-title":"Follow-up of 1887 patients receiving tumor necrosis-alpha antagonists: tuberculin skin test conversion and tuberculosis risk","volume":"12","author":"Cagatay","year":"2018","journal-title":"Clin Respir J"},{"key":"2022082312072164400_CIT0266","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/ecco-jcc\/jjw129","article-title":"Negative screening does not rule out the risk of tuberculosis in patients with inflammatory bowel disease undergoing anti-TNF treatment: a descriptive study on the GETAID cohort","volume":"10","author":"Abitbol","year":"2016","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0267","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/ecco-jcc\/jjy104","article-title":"Serial tuberculin skin tests improve the detection of latent tuberculosis infection in patients with inflammatory bowel disease","volume":"12","author":"Taxonera","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0268","doi-asserted-by":"crossref","first-page":"340","DOI":"10.14309\/ajg.0000000000000527","article-title":"Risk of tuberculosis in patients with inflammatory bowel disease on infliximab or adalimumab is dependent on the local disease burden of tuberculosis: a systematic review and meta-analysis","volume":"115","author":"Kedia","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"2022082312072164400_CIT0269","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1093\/ecco-jcc\/jjx022","article-title":"Early tuberculin skin test for the diagnosis of latent tuberculosis infection in patients with inflammatory bowel disease","volume":"11","author":"Taxonera","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0270","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","article-title":"ECCO-ESGAR Guideline for Diagnostic Assessment in IBD. Part 1: initial diagnosis, monitoring of known IBD, detection of complications","volume":"13","author":"Maaser","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0271","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1183\/09031936.02.00261402","article-title":"European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization [WHO], International Union Against Tuberculosis and Lung Disease [IUATLD] and Royal Netherlands Tuberculosis Association [KNCV] Working Group","volume":"19","author":"Broekmans","year":"2002","journal-title":"Eur Respir J"},{"key":"2022082312072164400_CIT0272","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1164\/rccm.2508001","article-title":"American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America: controlling tuberculosis in the United States","volume":"172","author":"American Thoracic S","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"2022082312072164400_CIT0273","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/gut.2005.076034","article-title":"Preventing TB in patients with Crohn\u2019s disease needing infliximab or other anti-TNF therapy","volume":"54","author":"Rampton","year":"2005","journal-title":"Gut"},{"key":"2022082312072164400_CIT0274","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1056\/NEJMsa031667","article-title":"Priorities for the treatment of latent tuberculosis infection in the United States","volume":"350","author":"Horsburgh","year":"2004","journal-title":"N Engl J Med"},{"key":"2022082312072164400_CIT0275","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1183\/09031936.00115110","article-title":"Interferon-\u03b3 release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis","volume":"37","author":"Diel","year":"2011","journal-title":"Eur Respir J"},{"key":"2022082312072164400_CIT0276","doi-asserted-by":"crossref","first-page":"19373","DOI":"10.2807\/ese.14.43.19373-en","article-title":"Estimating diagnostic accuracy of tests for latent tuberculosis infection without a gold standard among health care workers","volume":"14","author":"Girardi","year":"2009","journal-title":"Euro Surveill"},{"key":"2022082312072164400_CIT0277","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.trstmh.2005.03.001","article-title":"Tuberculin reactivity in adults after 50 years of universal Bacille Calmette-Guerin vaccination in Taiwan","volume":"99","author":"Yeh","year":"2005","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2022082312072164400_CIT0278","first-page":"1192","article-title":"False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria?","volume":"10","author":"Farhat","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"2022082312072164400_CIT0279","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0210-5705(03)70338-0","article-title":"[Consensus guideline on tuberculosis and treatment of inflammatory bowel disease with infliximab. Spanish Working Group on Crohn Disease and Ulcerative Colitis]","volume":"26","author":"Obrador","year":"2003","journal-title":"Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0280","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/ibd.20496","article-title":"Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy","volume":"14","author":"Zabana","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0281","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.22768","article-title":"Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection","volume":"57","author":"G\u00f3mez-Reino","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2022082312072164400_CIT0282","first-page":"474","article-title":"Infliximab does not suppress the tuberculin skin test [purified protein derivative]","volume":"34","author":"Hatemi","year":"2007","journal-title":"J Rheumatol"},{"key":"2022082312072164400_CIT0283","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.autrev.2015.01.011","article-title":"Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice","volume":"14","author":"Cantini","year":"2015","journal-title":"Autoimmun Rev"},{"key":"2022082312072164400_CIT0284","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1164\/rccm.201006-0974OC","article-title":"Negative and positive predictive value of a whole-blood interferon-\u03b3 release assay for developing active tuberculosis: an update","volume":"183","author":"Diel","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2022082312072164400_CIT0285","doi-asserted-by":"crossref","first-page":"15","DOI":"10.21307\/pjm-2019-002","article-title":"Interferon gamma release assays in patients with respiratory isolates of non-tuberculous mycobacteria - a preliminary study","volume":"68","author":"Augustynowicz-Kope\u0107","year":"2019","journal-title":"Pol J Microbiol"},{"key":"2022082312072164400_CIT0286","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1002\/ibd.22901","article-title":"Performance of interferon-gamma release assays in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"18","author":"Shahidi","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0287","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1002\/ibd.21605","article-title":"Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection","volume":"17","author":"B\u00e9lard","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0288","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ibd.21427","article-title":"Factors impacting the results of interferon-\u03b3 release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases","volume":"17","author":"Papay","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0289","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/01.MIB.0000438429.38423.62","article-title":"T-cell profiling and the immunodiagnosis of latent tuberculosis infection in patients with inflammatory bowel disease","volume":"20","author":"Arias-Guill\u00e9n","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0290","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.3899\/jrheum.130303","article-title":"Screening for latent tuberculosis infection in patients with chronic inflammatory arthritis: discrepancies between tuberculin skin test and interferon-\u03b3 release assay results","volume":"40","author":"Costantino","year":"2013","journal-title":"J Rheumatol"},{"key":"2022082312072164400_CIT0291","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/art.34382","article-title":"Interferon-\u03b3 release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis","volume":"64","author":"Hsia","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2022082312072164400_CIT0292","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1128\/CMR.00034-13","article-title":"Gamma interferon release assays for detection of Mycobacterium tuberculosis infection","volume":"27","author":"Pai","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"2022082312072164400_CIT0293","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1136\/annrheumdis-2012-201979","article-title":"You can\u2019t always get what you want, but if you try sometimes [with two tests\u2013TST and IGRA\u2013for tuberculosis] you get what you need","volume":"71","author":"Winthrop","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2022082312072164400_CIT0294","first-page":"1","article-title":"Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010","volume":"59","author":"Mazurek","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"2022082312072164400_CIT0295","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.arbres.2015.04.016","article-title":"Consensus document on prevention and treatment of tuberculosis in patients for biological treatment","volume":"52","author":"Mir Viladrich","year":"2016","journal-title":"Arch Bronconeumol"},{"key":"2022082312072164400_CIT0296","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3109\/00365548.2014.938691","article-title":"Diagnosis of latent tuberculosis infection before initiation of anti-tumor necrosis factor therapy using both tuberculin skin test and QuantiFERON-TB Gold In Tube assay","volume":"46","author":"Kim","year":"2014","journal-title":"Scand J Infect Dis"},{"key":"2022082312072164400_CIT0297","doi-asserted-by":"crossref","first-page":"e97366","DOI":"10.1371\/journal.pone.0097366","article-title":"Tuberculin skin testing and treatment modulates interferon-gamma release assay results for latent tuberculosis in migrants","volume":"9","author":"O\u2019Shea","year":"2014","journal-title":"PLoS One"},{"key":"2022082312072164400_CIT0298","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"Carmona","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2022082312072164400_CIT0299","first-page":"100","article-title":"Infliximab therapy in Crohn\u2019s disease: safety issues","volume":"61","author":"Hommes","year":"2003","journal-title":"Neth J Med"},{"key":"2022082312072164400_CIT0300","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMcp021045","article-title":"Clinical practice. Latent tuberculosis infection","volume":"347","author":"Jasmer","year":"2002","journal-title":"N Engl J Med"},{"key":"2022082312072164400_CIT0301","first-page":"S221","article-title":"This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society [ATS] and the Centers for Disease Control and Prevention [CDC]. This statement was endorsed by the Council of the Infectious Diseases Society of America. [IDSA], September 1999, and the sections of this statement","volume":"161","author":"Targeted tuberculin testing and treatment of latent tuberculosis infection","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"2022082312072164400_CIT0302","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"2022082312072164400_CIT0303","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa1714283","article-title":"Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults","volume":"379","author":"Menzies","year":"2018","journal-title":"N Engl J Med"},{"key":"2022082312072164400_CIT0304","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1056\/NEJMra1816149","article-title":"Drug-induced liver injury - types and phenotypes","volume":"381","author":"Hoofnagle","year":"2019","journal-title":"N Engl J Med"},{"key":"2022082312072164400_CIT0305","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/MOG.0b013e3280b17dfb","article-title":"Drug-induced liver disease in 2006","volume":"23","author":"Arundel","year":"2007","journal-title":"Curr Opin Gastroenterol"},{"key":"2022082312072164400_CIT0306","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1001\/jama.281.11.1014","article-title":"Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic","volume":"281","author":"Nolan","year":"1999","journal-title":"JAMA"},{"key":"2022082312072164400_CIT0307","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1136\/ard.2002.004598","article-title":"High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors","volume":"62","author":"Vanhoof","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"2022082312072164400_CIT0308","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ard.2007.072967","article-title":"Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis","volume":"67","author":"Takeuchi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2022082312072164400_CIT0309","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/thx.2005.046797","article-title":"BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment","volume":"60","author":"British Thoracic Society Standards of Care","year":"2005","journal-title":"Thorax"},{"key":"2022082312072164400_CIT0310","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1465-9921-8-5","article-title":"Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study","volume":"8","author":"Goletti","year":"2007","journal-title":"Respir Res"},{"key":"2022082312072164400_CIT0311","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1038\/ajg.2015.284","article-title":"Inflammatory bowel disease patients are at increased risk of invasive pneumococcal disease: a nationwide Danish cohort study 1977-2013","volume":"110","author":"Kants\u00f8","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"2022082312072164400_CIT0312","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2011.1692","article-title":"Initiation of tumor necrosis factor-\u03b1 antagonists and the risk of hospitalization for infection in patients with autoimmune diseases","volume":"306","author":"Grijalva","year":"2011","journal-title":"JAMA"},{"key":"2022082312072164400_CIT0313","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1097\/MD.0000000000000417","article-title":"Pneumococcal vaccination rates in VHA patients with inflammatory bowel disease","volume":"94","author":"Case","year":"2015","journal-title":"Medicine [Baltimore]"},{"key":"2022082312072164400_CIT0314","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/23744235.2019.1638519","article-title":"Persistence of antibodies to pneumococcal conjugate vaccine compared with polysaccharide vaccine in patients with Crohn\u2019s disease - one year follow up","volume":"51","author":"Kants\u00f8","year":"2019","journal-title":"Infect Dis"},{"key":"2022082312072164400_CIT0315","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ajg.2009.523","article-title":"Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease","volume":"105","author":"Melmed","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"2022082312072164400_CIT0316","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/ibd.21800","article-title":"Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study","volume":"18","author":"Fiorino","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0317","first-page":"1122","article-title":"Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use","volume":"12","author":"Brodmerkel","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"2022082312072164400_CIT0318","doi-asserted-by":"crossref","first-page":"5464","DOI":"10.1016\/j.vaccine.2015.08.011","article-title":"Immunosuppressive drugs impairs antibody response of the polysaccharide and conjugated pneumococcal vaccines in patients with Crohn\u2019s disease","volume":"33","author":"Kants\u00f8","year":"2015","journal-title":"Vaccine"},{"key":"2022082312072164400_CIT0319","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.14309\/ajg.0000000000000289","article-title":"High immunogenicity of the pneumococcal conjugated vaccine in immunocompromised adults with inflammatory bowel disease","volume":"114","author":"Pittet","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"2022082312072164400_CIT0320","author":"Centers for Disease Control and Prevention","year":"2020"},{"key":"2022082312072164400_CIT0321","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1128\/JCM.02675-15","article-title":"Diagnostic accuracy of PCR alone and compared with urinary antigen testing for detection of Legionella spp.: a systematic review","volume":"54","author":"Avni","year":"2016","journal-title":"J Clin Microbiol"},{"key":"2022082312072164400_CIT0322","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.idc.2016.10.003","article-title":"Legionnaire\u2019s disease and immunosuppressive drugs","volume":"31","author":"Htwe","year":"2017","journal-title":"Infect Dis Clin North Am"},{"key":"2022082312072164400_CIT0323","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1378\/chest.12-2820","article-title":"Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study","volume":"144","author":"Lanternier","year":"2013","journal-title":"Chest"},{"key":"2022082312072164400_CIT0324","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.rmed.2014.04.017","article-title":"Legionellosis and biologic therapies","volume":"108","author":"Bodro","year":"2014","journal-title":"Respir Med"},{"key":"2022082312072164400_CIT0325","doi-asserted-by":"crossref","first-page":"524","DOI":"10.17235\/reed.2016.4213\/2016","article-title":"Community-acquired pneumonia by Legionella pneumophila. Do we need to include new recommendations for inflammatory bowel disease patients under immunomodulators?","volume":"108","author":"Fern\u00e1ndez Llamas","year":"2016","journal-title":"Rev Esp Enferm Dig"},{"key":"2022082312072164400_CIT0326","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2146\/ajhp160010","article-title":"Legionella pneumophila pneumonia possibly due to ustekinumab therapy in a patient with Crohn\u2019s disease","volume":"74","author":"Borr\u00e1s-Blasco","year":"2017","journal-title":"Am J Health Syst Pharm"},{"key":"2022082312072164400_CIT0327","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.1086\/429996","article-title":"Reactivation of latent granulomatous infections by infliximab","volume":"41[Suppl 3]","author":"Wallis","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2022082312072164400_CIT0328","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","article-title":"Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"54","author":"Dixon","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2022082312072164400_CIT0329","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2022082312072164400_CIT0330","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1002\/art.20639","article-title":"Disseminated Salmonella typhimurium infection secondary to infliximab treatment","volume":"50","author":"Fu","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2022082312072164400_CIT0331","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1080\/00365540410021171-1","article-title":"Septic arthritis due to Salmonella enteritidis associated with infliximab use","volume":"37","author":"Katsarolis","year":"2005","journal-title":"Scand J Infect Dis"},{"key":"2022082312072164400_CIT0332","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/rheumatology\/kei123","article-title":"Two cases of serious food-borne infection in patients treated with anti-TNF-alpha. Are we doing enough to reduce the risk?","volume":"45","author":"Makkuni","year":"2006","journal-title":"Rheumatology"},{"key":"2022082312072164400_CIT0333","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1002\/art.11151","article-title":"Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression","volume":"48","author":"Netea","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2022082312072164400_CIT0334","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1080\/00365540600786549","article-title":"Fatal Salmonella enteritidis septicaemia in a rheumatoid arthritis patient treated with a TNF-alpha antagonist","volume":"39","author":"Rijkeboer","year":"2007","journal-title":"Scand J Infect Dis"},{"key":"2022082312072164400_CIT0335","doi-asserted-by":"crossref","first-page":"934657","DOI":"10.1155\/2014\/934657","article-title":"Invasive Salmonellosis by the very rare Salmonella choleraesuis in a returning traveler on a tumor necrosis factor-\u03b1 inhibitor","volume":"2014","author":"Eke","year":"2014","journal-title":"Case Rep Med"},{"key":"2022082312072164400_CIT0336","doi-asserted-by":"crossref","first-page":"e00500","DOI":"10.1016\/j.idcr.2019.e00500","article-title":"Nontyphoidal Salmonella purulent pericarditis presenting with pericardial tamponade in a patient on infliximab therapy","volume":"15","author":"Saddler","year":"2019","journal-title":"IDCases"},{"key":"2022082312072164400_CIT0337","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1099\/jmm.0.059352-0","article-title":"Salmonella enterica serovar Minnesota urosepsis in a patient with Crohn\u2019s disease in the absence of recent or current gastrointestinal symptoms","volume":"62","author":"Steinebrunner","year":"2013","journal-title":"J Med Microbiol"},{"key":"2022082312072164400_CIT0338","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00508-010-1403-4","article-title":"Salmonella typhimurium osteomyelitis of the femur in patient with Crohn\u2019s disease","volume":"122","author":"Gulan","year":"2010","journal-title":"Wien Klin Wochenschr"},{"key":"2022082312072164400_CIT0339","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1093\/ibd\/izy347","article-title":"A case of IBD immunosuppression related salmonella aortitis requiring emergency vascular grafting","volume":"25","author":"Sado","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0340","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/ibd.21033","article-title":"Salmonella septic arthritis in a patient with Crohn\u2019s disease on infliximab","volume":"16","author":"Rim","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0341","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.2106\/JBJS.CC.16.00045","article-title":"Bilateral salmonella septic arthritis of the hip in a patient with Crohn disease: a case report","volume":"6","author":"Mansour","year":"2016","journal-title":"JBJS Case Connect"},{"key":"2022082312072164400_CIT0342","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1146\/annurev.me.37.020186.001415","article-title":"Infections of the gastrointestinal tract in the immunocompromised patient","volume":"37","author":"Bodey","year":"1986","journal-title":"Annu Rev Med"},{"key":"2022082312072164400_CIT0343","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/apt.15097","article-title":"Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease","volume":"49","author":"Shivaji","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2022082312072164400_CIT0344","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1080\/17474124.2018.1545574","article-title":"Adverse events in IBD therapy: the 2018 update","volume":"12","author":"Quezada","year":"2018","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0345","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/1751-2980.12091","article-title":"Infections and inflammatory bowel disease: challenges in Asia","volume":"14","author":"Ng","year":"2013","journal-title":"J Dig Dis"},{"key":"2022082312072164400_CIT0346","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1086\/338465","article-title":"Listeria monocytogenes: clinical and experimental update","volume":"185[Suppl 1","author":"Wing","year":"2002","journal-title":"J Infect Dis"},{"key":"2022082312072164400_CIT0347","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.crohns.2012.04.018","article-title":"Listeria infection in patients on anti-TNF treatment: report of two cases and review of the literature","volume":"7","author":"Abreu","year":"2013","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0348","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/MPG.0b013e3181a70f3a","article-title":"Listeria meningitis after infliximab treatment of ulcerative colitis","volume":"50","author":"Chuang","year":"2010","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2022082312072164400_CIT0349","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gastrohep.2009.03.002","article-title":"[Meningitis due to Listeria monocytogenes during adalimumab therapy]","volume":"32","author":"Gil","year":"2009","journal-title":"Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0350","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/RHU.0b013e3181bf93cd","article-title":"Systemic listeriosis with adalimumab therapy","volume":"15","author":"Murphy","year":"2009","journal-title":"J Clin Rheumatol"},{"key":"2022082312072164400_CIT0351","first-page":"854","article-title":"Listeria monocytogenes infection in patients with rheumatic diseases on TNF-alpha antagonist therapy: the Spanish Study Group experience","volume":"26","author":"Pe\u00f1a-Sagredo","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"2022082312072164400_CIT0352","doi-asserted-by":"crossref","first-page":"614","DOI":"10.4321\/S1130-01082010001000014","article-title":"Listeria monocytogenes infection in patients with inflammatory bowel diseases receiving anti-tumor necrosis factor therapy","volume":"102","author":"Ramos","year":"2010","journal-title":"Rev Esp Enferm Dig"},{"key":"2022082312072164400_CIT0353","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/art.10758","article-title":"Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents","volume":"48","author":"Slifman","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2022082312072164400_CIT0354","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1159\/000481165","article-title":"Listeria monocytogenes brain abscess in Crohn\u2019s disease treated with adalimumab","volume":"11","author":"Atsawarungruangkit","year":"2017","journal-title":"Case Rep Gastroenterol"},{"key":"2022082312072164400_CIT0355","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s12328-019-01005-6","article-title":"Septicemic listeriosis during adalimumab- and golimumab-based treatment for ulcerative colitis: case presentation and literature review","volume":"13","author":"Horigome","year":"2020","journal-title":"Clin J Gastroenterol"},{"key":"2022082312072164400_CIT0356","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1097\/MEG.0000000000000188","article-title":"Listeria monocytogenes infection in inflammatory bowel disease patients: case series and review of the literature","volume":"26","author":"Miranda-Bautista","year":"2014","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0357","doi-asserted-by":"crossref","first-page":"485","DOI":"10.18433\/J3GG6D","article-title":"Risk of infections of biological therapies with accent on inflammatory bowel disease","volume":"17","author":"Nanau","year":"2014","journal-title":"J Pharm Pharm Sci"},{"key":"2022082312072164400_CIT0358","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s11845-015-1355-9","article-title":"Listeria meningitis complicating a patient with ulcerative colitis on concomitant infliximab and hydrocortisone","volume":"185","author":"Parihar","year":"2016","journal-title":"Ir J Med Sci"},{"key":"2022082312072164400_CIT0359","first-page":"6216128","article-title":"Listeria rhombencephalitis complicating anti-TNF treatment during an acute flare of Crohn\u2019s colitis","volume":"2016","author":"Stratton","year":"2016","journal-title":"Case Rep Gastrointest Med"},{"key":"2022082312072164400_CIT0360","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.2169\/internalmedicine.0695-18","article-title":"Listeria meningitis during infliximab-based treatment for ulcerative colitis","volume":"57","author":"Tsuchiya","year":"2018","journal-title":"Intern Med"},{"key":"2022082312072164400_CIT0361","first-page":"685","article-title":"[Listeriosis of central nervous system in patients with ulcerative colitis - case study]","volume":"70","author":"\u017bak-Go\u0142\u0105b","year":"2017","journal-title":"Wiad Lek"},{"key":"2022082312072164400_CIT0362","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1017\/ice.2014.39","article-title":"Comorbidities, exposure to medications, and the risk of community-acquired Clostridium difficile infection: a systematic review and meta-analysis","volume":"36","author":"Furuya-Kanamori","year":"2015","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2022082312072164400_CIT0363","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1097\/MIB.0000000000000219","article-title":"Clostridium difficile and pediatric inflammatory bowel disease: a prospective, comparative, multicenter, ESPGHAN study","volume":"20","author":"Martinelli","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0364","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2017.04.044","article-title":"Higher incidence of Clostridium difficile infection among individuals with inflammatory bowel disease","volume":"153","author":"Singh","year":"2017","journal-title":"Gastroenterology"},{"key":"2022082312072164400_CIT0365","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/ecco-jcc\/jjy143","article-title":"Risk factors associated with Clostridium difficile infection in inflammatory bowel disease: a systematic review and meta-analysis","volume":"13","author":"Balram","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0366","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.dld.2017.01.162","article-title":"Clostridium difficile infection in acute flares of inflammatory bowel disease: a prospective study","volume":"49","author":"Sokol","year":"2017","journal-title":"Dig Liver Dis"},{"key":"2022082312072164400_CIT0367","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00384-018-3105-8","article-title":"Impact of superimposed Clostridium difficile infection in Crohn\u2019s or ulcerative colitis flares in the outpatient setting","volume":"33","author":"Garcia","year":"2018","journal-title":"Int J Colorectal Dis"},{"key":"2022082312072164400_CIT0368","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/1751-2980.12798","article-title":"High incidence and morbidity of Clostridium difficile infection among hospitalized patients with inflammatory bowel disease: a prospective observational cohort study","volume":"20","author":"Chen","year":"2019","journal-title":"J Dig Dis"},{"key":"2022082312072164400_CIT0369","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1097\/MIB.0000000000001251","article-title":"Lasting impact of Clostridium difficile infection in inflammatory bowel disease: a propensity score matched analysis","volume":"23","author":"Anderson","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0370","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1097\/MIB.0b013e3182807563","article-title":"Health care burden of Clostridium difficile infection in hospitalized children with inflammatory bowel disease","volume":"19","author":"Pant","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0371","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2019.3849","article-title":"Diagnosis and treatment of Clostridioides [Clostridium] difficile infection in adults in 2020","volume":"323","author":"Rao","year":"2020","journal-title":"JAMA"},{"key":"2022082312072164400_CIT0372","first-page":"78","article-title":"Comparison of Clostridioides difficile stool toxin concentrations in adults with symptomatic infection and asymptomatic carriage using an ultrasensitive quantitative immunoassay","volume":"68","author":"Pollock","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2022082312072164400_CIT0373","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1093\/cid\/cir201","article-title":"Effective utilization of evolving methods for the laboratory diagnosis of Clostridium difficile infection","volume":"52","author":"Kufelnicka","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2022082312072164400_CIT0374","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ajic.2016.09.007","article-title":"Diagnostic testing methods for Clostridium difficile infection: a statewide survey of Ohio acute care hospitals","volume":"45","author":"Wong","year":"2017","journal-title":"Am J Infect Control"},{"key":"2022082312072164400_CIT0375","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/j.cmi.2016.03.010","article-title":"European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection","volume":"22[Suppl 4]","author":"Crobach","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2022082312072164400_CIT0376","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1086\/651706","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America [SHEA] and the Infectious Diseases Society of America [IDSA]","volume":"31","author":"Cohen","year":"2010","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2022082312072164400_CIT0377","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S1473-3099(08)70233-0","article-title":"Diagnosis of Clostridium difficile infection by toxin detection kits: a systematic review","volume":"8","author":"Planche","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"2022082312072164400_CIT0378","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/cid\/cis840","article-title":"Impact of the type of diagnostic assay on Clostridium difficile infection and complication rates in a mandatory reporting program","volume":"56","author":"Longtin","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2022082312072164400_CIT0379","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1099\/jmm.0.46680-0","article-title":"Evaluation of real-time PCR and conventional diagnostic methods for the detection of Clostridium difficile-associated diarrhoea in a prospective multicentre study","volume":"56","author":"van den Berg","year":"2007","journal-title":"J Med Microbiol"},{"key":"2022082312072164400_CIT0380","doi-asserted-by":"crossref","first-page":"758","DOI":"10.7326\/0003-4819-145-10-200611210-00008","article-title":"Narrative review: the new epidemic of Clostridium difficile-associated enteric disease","volume":"145","author":"Bartlett","year":"2006","journal-title":"Ann Intern Med"},{"key":"2022082312072164400_CIT0381","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1017\/S0950268816001096","article-title":"Role of binary toxin in the outcome of Clostridium difficile infection in a non-027 ribotype setting: CORRIGENDUM","volume":"144","author":"Reigadas","year":"2016","journal-title":"Epidemiol Infect"},{"key":"2022082312072164400_CIT0382","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s10620-020-06205-6","article-title":"Diagnostic modality of Clostridioides difficile infection predicts treatment response and outcomes in inflammatory bowel disease","volume":"66","author":"Gupta","year":"2021","journal-title":"Dig Dis Sci"},{"key":"2022082312072164400_CIT0383","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1445-5994.2007.01403.x","article-title":"Clostridium difficile-associated diarrhoea","volume":"37","author":"Elliott","year":"2007","journal-title":"Intern Med J"},{"key":"2022082312072164400_CIT0384","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.crohns.2009.11.001","article-title":"Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection","volume":"4","author":"Ben-Horin","year":"2010","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0385","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/cid\/ciu313","article-title":"Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials","volume":"59","author":"Johnson","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2022082312072164400_CIT0386","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1086\/519265","article-title":"A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity","volume":"45","author":"Zar","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2022082312072164400_CIT0387","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"364","author":"Louie","year":"2011","journal-title":"N Engl J Med"},{"key":"2022082312072164400_CIT0388","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(11)70374-7","article-title":"Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomized controlled trial","volume":"12","author":"Cornely","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"2022082312072164400_CIT0389","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/cid\/ciy149","article-title":"Clinical Practice Guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America [IDSA] and Society for Healthcare Epidemiology of America [SHEA]","volume":"66","author":"McDonald","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2022082312072164400_CIT0390","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1093\/cid\/cis462","article-title":"Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin","volume":"55[Suppl 2]","author":"Cornely","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2022082312072164400_CIT0391","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/1469-0691.12418","article-title":"European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection","volume":"20[Suppl 2]","author":"Debast","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2022082312072164400_CIT0392","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1093\/cid\/ciy721","article-title":"Low cure rates in controlled trials of fecal microbiota transplantation for recurrent Clostridium difficile infection: a systematic review and meta-analysis","volume":"68","author":"Tariq","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2022082312072164400_CIT0393","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/ecco-jcc\/jjy031","article-title":"Effect of faecal microbiota transplantation for treatment of Clostridium difficile infection in patients with inflammatory bowel disease: a systematic review and meta-analysis of cohort studies","volume":"12","author":"Chen","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0394","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/gastro\/gox018","article-title":"Fecal microbiota transplantation for Clostridium difficile infection in patients with ileal pouches","volume":"5","author":"Lan","year":"2017","journal-title":"Gastroenterol Rep"},{"key":"2022082312072164400_CIT0395","first-page":"CD006095","article-title":"Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children","volume":"12","author":"Goldenberg","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2022082312072164400_CIT0396","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa1602615","article-title":"Bezlotoxumab for prevention of recurrent Clostridium difficile infection","volume":"376","author":"Wilcox","year":"2017","journal-title":"N Engl J Med"},{"key":"2022082312072164400_CIT0397","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.cgh.2006.12.028","article-title":"Impact of Clostridium difficile on inflammatory bowel disease","volume":"5","author":"Issa","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0398","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.patbio.2015.04.003","article-title":"Meningococcal vaccines: current state and future outlook","volume":"63","author":"Leca","year":"2015","journal-title":"Pathol Biol"},{"key":"2022082312072164400_CIT0399","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6909a1","article-title":"Meningococcal vaccination: recommendations of the advisory committee on immunization practices, United States, 2020","volume":"69","author":"Mbaeyi","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"2022082312072164400_CIT0400","volume-title":"Canadian Immunization Guide","author":"Public Health Agency of Canada","year":"2015"},{"key":"2022082312072164400_CIT0401","volume-title":"Meningococcal Disease: Recommended Vaccinations.","author":"European Center for Disease Prevention and Control [ECDC].","year":"2020"},{"key":"2022082312072164400_CIT0402","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1111\/j.1572-0241.2005.41939.x","article-title":"Depletion of immunoglobulin M memory B cells is associated with splenic hypofunction in inflammatory bowel disease","volume":"100","author":"Di Sabatino","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"2022082312072164400_CIT0403","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0140-6736(74)91695-X","article-title":"Hyposplenism in ulcerative colitis","volume":"2","author":"Ryan","year":"1974","journal-title":"Lancet"},{"key":"2022082312072164400_CIT0404","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S0140-6736(74)91905-9","article-title":"Hyposplenism and ulcerative colitis","volume":"304","author":"Ardeman","year":"1974","journal-title":"Lancet"},{"key":"2022082312072164400_CIT0405","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1136\/gut.19.1.50","article-title":"Hyposplenism in inflammatory bowel disease","volume":"19","author":"Ryan","year":"1978","journal-title":"Gut"},{"key":"2022082312072164400_CIT0406","first-page":"463","article-title":"Further experience of hyposplenism in inflammatory bowel disease","volume":"50","author":"Palmer","year":"1981","journal-title":"Q J Med"},{"key":"2022082312072164400_CIT0407","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.crohns.2012.06.012","article-title":"Meningococcal meningoencephalitis after certolizumab pegol treatment in a patient with Crohn\u2019s disease","volume":"7","author":"Majumder","year":"2013","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0408","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.annder.2019.08.014","article-title":"M\u00e9ningococc\u00e9mie subaigu\u00eb sous adalimumab (Subacute meningococcaemia during adalimumab therapy)","volume":"146","author":"Salinas","year":"2019","journal-title":"Ann Dermatol Venereol"},{"key":"2022082312072164400_CIT0409","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/MCG.0000000000001365","article-title":"Patients with inflammatory bowel diseases are at higher risk for meningitis","volume":"55","author":"Kochar","year":"2021","journal-title":"J Clin Gastroenterol"},{"key":"2022082312072164400_CIT0410","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jama.1978.03280280045025","article-title":"Disseminated varicella complicating ulcerative colitis","volume":"239","author":"Keene","year":"1978","journal-title":"JAMA"},{"key":"2022082312072164400_CIT0411","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/postgradmedj-2016-134266","article-title":"Vaccination practices in patients with inflammatory bowel disease among general internal medicine physicians in the USA","volume":"93","author":"Gurvits","year":"2017","journal-title":"Postgrad Med J"},{"key":"2022082312072164400_CIT0412","doi-asserted-by":"crossref","first-page":"242","DOI":"10.5009\/gnl.2014.8.3.242","article-title":"Insufficient knowledge of Korean gastroenterologists regarding the vaccination of patients with inflammatory bowel disease","volume":"8","author":"Jung","year":"2014","journal-title":"Gut Liver"},{"key":"2022082312072164400_CIT0413","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022082312072164400_CIT0414","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2022082312072164400_CIT0415","doi-asserted-by":"crossref","first-page":"R174","DOI":"10.1186\/ar3497","article-title":"The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study","volume":"13","author":"Zhang","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2022082312072164400_CIT0416","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.2012.7304","article-title":"Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases","volume":"308","author":"Zhang","year":"2012","journal-title":"JAMA"},{"key":"2022082312072164400_CIT0417","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/MPG.0b013e3181bab351","article-title":"Varicella vaccination in children with inflammatory bowel disease receiving immunosuppressive therapy","volume":"50","author":"Lu","year":"2010","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2022082312072164400_CIT0418","article-title":"Inadvertent yellow fever vaccination of a patient with Crohn\u2019s disease treated with infliximab and methotrexate","volume":"2016","author":"Ekenberg","year":"2016","journal-title":"BMJ Case Rep"},{"key":"2022082312072164400_CIT0419","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/jtm.12209","article-title":"Yellow fever vaccination of a primary vaccinee during adalimumab therapy","volume":"22","author":"Nash","year":"2015","journal-title":"J Travel Med"},{"key":"2022082312072164400_CIT0420","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1055\/s-0042-109871","article-title":"Yellow fever vaccination during treatment with infliximab in a patient with ulcerative colitis: a case report","volume":"54","author":"R\u00fcddel","year":"2016","journal-title":"Z Gastroenterol"},{"key":"2022082312072164400_CIT0421","doi-asserted-by":"crossref","first-page":"taaa126","DOI":"10.1093\/jtm\/taaa126","article-title":"Safety and immunogenicity of a primary yellow fever vaccination under low-dose methotrexate therapy - a prospective multi-centre pilot study1","volume":"27","author":"Buhler","year":"2020","journal-title":"J Travel Med"},{"key":"2022082312072164400_CIT0422","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/ajg.2016.21","article-title":"Safety and efficacy of live measles vaccine administered to a Crohn\u2019s disease patient receiving vedolizumab","volume":"111","author":"Wichmann","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2022082312072164400_CIT0423","first-page":"1","article-title":"Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices [ACIP]","volume":"62","author":"McLean","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"2022082312072164400_CIT0424","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10620-018-5321-z","article-title":"Immunosuppression does not affect antibody concentrations to measles, mumps, and rubella in patients with inflammatory bowel disease","volume":"64","author":"Caldera","year":"2019","journal-title":"Dig Dis Sci"},{"key":"2022082312072164400_CIT0425","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.vaccine.2017.01.048","article-title":"Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation - a systematic review of randomised trials, observational studies and case reports","volume":"35","author":"Croce","year":"2017","journal-title":"Vaccine"},{"key":"2022082312072164400_CIT0426","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/MEG.0000000000000280","article-title":"A \u2018cocoon immunization strategy\u2019 among patients with inflammatory bowel disease","volume":"27","author":"Waszczuk","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0427","first-page":"1","volume-title":"Chapter 6: Contraindications and Special Considerations","year":"2017"},{"key":"2022082312072164400_CIT0428","volume-title":"The Green Book: Immunisation Against Infectious Disease"},{"key":"2022082312072164400_CIT0429","volume-title":"C.S. Vaccination of Immunocompromised or Chronically Ill Children and\/or Adults."},{"key":"2022082312072164400_CIT0430","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00228-008-0478-6","article-title":"Clinical pharmacology and pharmacogenetics of thiopurines","volume":"64","author":"Sahasranaman","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"2022082312072164400_CIT0431","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/j.1552-4604.1990.tb03606.x","article-title":"Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients","volume":"30","author":"Chan","year":"1990","journal-title":"J Clin Pharmacol"},{"key":"2022082312072164400_CIT0432"},{"key":"2022082312072164400_CIT0433","doi-asserted-by":"crossref","first-page":"6491","DOI":"10.3748\/wjg.v21.i21.6491","article-title":"Nocardia infections among immunomodulated inflammatory bowel disease patients: a review","volume":"21","author":"Abreu","year":"2015","journal-title":"World J Gastroenterol"},{"key":"2022082312072164400_CIT0434","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.12659\/AJCR.906391","article-title":"Disseminated nocardiosis associated with treatment with infliximab in a patient with ulcerative colitis","volume":"18","author":"Garner","year":"2017","journal-title":"Am J Case Rep"},{"key":"2022082312072164400_CIT0435","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1111\/jgh.15256","article-title":"Invasive nocardiosis, disseminated varicella zoster reactivation, and pneumocystis jiroveci pneumonia associated with tofacitinib and concomitant systemic corticosteroid use in ulcerative colitis","volume":"35","author":"Verstockt","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0436","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44[Suppl 2]","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2022082312072164400_CIT0437","first-page":"2432","article-title":"Primary cutaneous Nocardia otitidiscaviarum infection in a patient with rheumatoid arthritis treated with infliximab","volume":"32","author":"Fabre","year":"2005","journal-title":"J Rheumatol"},{"key":"2022082312072164400_CIT0438","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1503\/cmaj.1040563","article-title":"Cutaneous nocardiosis complicating management of Crohn\u2019s disease with infliximab and prednisone","volume":"171","author":"Singh","year":"2004","journal-title":"CMAJ"},{"key":"2022082312072164400_CIT0439","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1080\/00365521.2018.1500637","article-title":"When IBD is not IBD","volume":"53","author":"Verstockt","year":"2018","journal-title":"Scand J Gastroenterol"},{"key":"2022082312072164400_CIT0440","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/S2468-1253(18)30159-6","article-title":"Differential diagnosis of inflammatory bowel disease: imitations and complications","volume":"3","author":"Gecse","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0441","doi-asserted-by":"crossref","first-page":"749","DOI":"10.4269\/ajtmh.2002.66.749","article-title":"Serology and eosinophil count in the diagnosis and management of strongyloidiasis in a non-endemic area","volume":"66","author":"Loutfy","year":"2002","journal-title":"Am J Trop Med Hyg"},{"key":"2022082312072164400_CIT0442","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1097\/MIB.0b013e3182802a9b","article-title":"Increased risk of pneumocystis jiroveci pneumonia among patients with inflammatory bowel disease","volume":"19","author":"Long","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0443","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/jgh.14832","article-title":"Incidence and risk factors of Pneumocystis jirovecii pneumonia in Korean patients with inflammatory bowel disease","volume":"35","author":"Nam","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0444","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3389\/fped.2017.00161","article-title":"Pneumocystis jirovecii pneumonia in pediatric inflammatory bowel disease: a case report and literature review","volume":"5","author":"Lawrence","year":"2017","journal-title":"Front Pediatr"},{"key":"2022082312072164400_CIT0445","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1007\/s10620-015-3796-4","article-title":"Cost-effectiveness of prophylaxis against Pneumocystis jiroveci pneumonia in patients with Crohn\u2019s disease","volume":"60","author":"Okafor","year":"2015","journal-title":"Dig Dis Sci"},{"key":"2022082312072164400_CIT0446","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.cgh.2017.06.020","article-title":"Risk of pneumonia caused by Pneumocystis jiroveci in inflammatory bowel disease: the role of concomitant pulmonary comorbidities","volume":"17","author":"Macaluso","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0447","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.cgh.2016.11.037","article-title":"Low risk of pneumonia from Pneumocystis jirovecii infection in patients with inflammatory bowel disease receiving immune suppression","volume":"15","author":"Cotter","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0448","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1097\/MIB.0b013e318281f562","article-title":"Pneumocystis jiroveci pneumonia in inflammatory bowel disease: when should prophylaxis be considered?","volume":"19","author":"Okafor","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0449","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/apt.14794","article-title":"Long-term efficacy and safety of ustekinumab for Crohn\u2019s disease through the second year of therapy","volume":"48","author":"Sandborn","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2022082312072164400_CIT0450","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.cmi.2018.02.009","article-title":"ESCMID Study Group for Infections in Compromised Hosts [ESGICH] Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective [intracellular signaling pathways: tyrosine kinase and mTOR inhibitors]","volume":"24[Suppl 2]","author":"Reinwald","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2022082312072164400_CIT0451","volume-title":"Stockley\u2019s Drug Interactions.","author":"Preston","year":"2019","edition":"12"},{"key":"2022082312072164400_CIT0452","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1177\/1060028016650107","article-title":"Pneumocystis jirovecii pneumonia in the non-HIV-infected population","volume":"50","author":"Avino","year":"2016","journal-title":"Ann Pharmacother"},{"key":"2022082312072164400_CIT0453","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/jtm.12184","article-title":"Travelers with immune-mediated inflammatory diseases: are they different?","volume":"22","author":"Jaeger","year":"2015","journal-title":"J Travel Med"},{"key":"2022082312072164400_CIT0454","doi-asserted-by":"crossref","first-page":"288","DOI":"10.7861\/clinmedicine.18-4-288","article-title":"Health concerns associated with travelling with inflammatory bowel disease [IBD]: a questionnaire survey","volume":"18","author":"Philip","year":"2018","journal-title":"Clin Med"},{"key":"2022082312072164400_CIT0455","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/ecco-jcc\/jjy110","article-title":"A global survey of gastroenterologists\u2019 travel advice to patients with inflammatory bowel disease on immunosuppressive agents, and management of those visiting tuberculosis-endemic areas","volume":"12","author":"Chan","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0456","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/flgastro-2014-100548","article-title":"Travel health and pretravel preparation in the patient with inflammatory bowel disease","volume":"7","author":"Greveson","year":"2016","journal-title":"Frontline Gastroenterol"},{"key":"2022082312072164400_CIT0457","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.idh.2018.09.083","article-title":"Pre-travel counseling for immunocompromised travelers: a 12-year single-center retrospective review","volume":"24","author":"Tan","year":"2019","journal-title":"Infect Dis Health"},{"key":"2022082312072164400_CIT0458","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/flgastro-2012-100265","article-title":"Diarrhoeal episodes in travellers suffering from IBD","volume":"4","author":"Ellul","year":"2013","journal-title":"Frontline Gastroenterol"},{"key":"2022082312072164400_CIT0459","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1708-8305.2011.00543.x","article-title":"Symptoms of infectious diseases in immunocompromised travelers: a prospective study with matched controls","volume":"18","author":"Baaten","year":"2011","journal-title":"J Travel Med"},{"key":"2022082312072164400_CIT0460","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.cgh.2011.10.025","article-title":"Travel-associated health risks for patients with inflammatory bowel disease","volume":"10","author":"Ben-Horin","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0461","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/ajg.2013.138","article-title":"Opportunistic infections with anti-tumor necrosis factor-\u03b1 therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials","volume":"108","author":"Ford","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"2022082312072164400_CIT0462","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0025-6196(11)60839-2","article-title":"Fungal infections complicating tumor necrosis factor alpha blockade therapy","volume":"83","author":"Tsiodras","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"2022082312072164400_CIT0463","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.tmaid.2013.03.002","article-title":"Clinical findings and management of imported cutaneous leishmaniasis: report of 14 cases from Austria","volume":"11","author":"Poeppl","year":"2013","journal-title":"Travel Med Infect Dis"},{"key":"2022082312072164400_CIT0464","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1136\/thoraxjnl-2012-202974","article-title":"Tuberculosis during TNF-\u03b1 inhibitor therapy, despite screening","volume":"68","author":"Hofland","year":"2013","journal-title":"Thorax"},{"key":"2022082312072164400_CIT0465","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40794-019-0092-x","article-title":"Imported visceral leishmaniasis and immunosuppression in seven Norwegian patients","volume":"5","author":"Schwartz","year":"2019","journal-title":"Trop Dis Travel Med Vaccines"},{"key":"2022082312072164400_CIT0466","doi-asserted-by":"crossref","first-page":"9593865","DOI":"10.1155\/2018\/9593865","article-title":"Hepatic abscess in a returning traveler with Crohn\u2019s disease: differentiating amebic from pyogenic liver abscess","volume":"2018","author":"Gaut","year":"2018","journal-title":"Case Rep Med"},{"key":"2022082312072164400_CIT0467","doi-asserted-by":"crossref","first-page":"e005170","DOI":"10.1099\/jmmcr.0.005170","article-title":"Reactivation of latent Histoplasma and disseminated cytomegalovirus in a returning traveller with ulcerative colitis","volume":"5","author":"Lucey","year":"2018","journal-title":"JMM Case Rep"},{"key":"2022082312072164400_CIT0468","doi-asserted-by":"crossref","first-page":"e0212791","DOI":"10.1371\/journal.pone.0212791","article-title":"Approach to amoebic colitis: epidemiological, clinical and diagnostic considerations in a non-endemic context [Barcelona, 2007-2017]","volume":"14","author":"Roure","year":"2019","journal-title":"PLoS One"},{"key":"2022082312072164400_CIT0469","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/ijd.13588","article-title":"Evolution of cutaneous leishmaniasis in the last 30 years in a tertiary hospital of the European Mediterranean coast","volume":"56","author":"Marcoval","year":"2017","journal-title":"Int J Dermatol"},{"key":"2022082312072164400_CIT0470","volume-title":"International Travel and Health","year":"2012"},{"key":"2022082312072164400_CIT0471","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00054725-200205000-00009","article-title":"Role of infections in the manifestation or reactivation of inflammatory bowel diseases","volume":"8","author":"Stallmach","year":"2002","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0472","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1136\/gut.7.5.438","article-title":"Ulcerative post-dysenteric colitis","volume":"7","author":"Powell","year":"1966","journal-title":"Gut"},{"key":"2022082312072164400_CIT0473","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1136\/pgmj.61.712.173","article-title":"Yersinia colitis associated with Crohn\u2019s disease","volume":"61","author":"Treacher","year":"1985","journal-title":"Postgrad Med J"},{"key":"2022082312072164400_CIT0474","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/s41395-018-0211-8","article-title":"Enteric infections are common in patients with flares of inflammatory bowel disease","volume":"113","author":"Axelrad","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"2022082312072164400_CIT0475","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1002\/ibd.22903","article-title":"Pretravel preparation and travel-related morbidity in patients with inflammatory bowel disease","volume":"18","author":"Soonawala","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0476","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.3748\/wjg.v20.i15.4329","article-title":"Case-control study of factors that trigger inflammatory bowel disease flares","volume":"20","author":"Feagins","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2022082312072164400_CIT0477","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.crohns.2013.07.011","article-title":"High altitude journeys and flights are associated with an increased risk of flares in inflammatory bowel disease patients","volume":"8","author":"Vavricka","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0478","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.cgh.2019.11.036","article-title":"Evaluation of acute mountain sickness by unsedated transnasal esophagogastroduodenoscopy at high altitude","volume":"18","author":"Fruehauf","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0479","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1086\/515402","article-title":"Overwhelming parasitemia with Plasmodium falciparum infection in a patient receiving infliximab therapy for rheumatoid arthritis","volume":"44","author":"Geraghty","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2022082312072164400_CIT0480","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1371\/journal.pmed.0020245","article-title":"Inhibition of endothelial activation: a new way to treat cerebral malaria?","volume":"2","author":"Wassmer","year":"2005","journal-title":"PLoS Med"},{"key":"2022082312072164400_CIT0481","doi-asserted-by":"crossref","first-page":"taz089","DOI":"10.1093\/jtm\/taz089","article-title":"Drug interactions with antimalarial medications in older travelers: a clinical guide","volume":"27","author":"Lewis","year":"2020","journal-title":"J Travel Med"},{"key":"2022082312072164400_CIT0482","doi-asserted-by":"crossref","first-page":"e13792","DOI":"10.1097\/MD.0000000000013792","article-title":"The clinical effects of probiotics for inflammatory bowel disease: a meta-analysis","volume":"97","author":"Jia","year":"2018","journal-title":"Medicine"},{"key":"2022082312072164400_CIT0483","doi-asserted-by":"crossref","first-page":"e0228846","DOI":"10.1371\/journal.pone.0228846","article-title":"Assessing the efficacy and safety of fecal microbiota transplantation and probiotic VSL#3 for active ulcerative colitis: a systematic review and meta-analysis","volume":"15","author":"Dang","year":"2020","journal-title":"PLoS One"},{"key":"2022082312072164400_CIT0484","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(98)06343-0","article-title":"Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial","volume":"354","author":"Rembacken","year":"1999","journal-title":"Lancet"},{"key":"2022082312072164400_CIT0485","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1136\/gut.2003.037747","article-title":"Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine","volume":"53","author":"Kruis","year":"2004","journal-title":"Gut"},{"key":"2022082312072164400_CIT0486","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1086\/368080","article-title":"Safety of probiotics that contain lactobacilli or bifidobacteria","volume":"36","author":"Borriello","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2022082312072164400_CIT0487","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/clinids\/22.3.564","article-title":"Lactobacilli and bacteremia in southern Finland, 1989-1992","volume":"22","author":"Saxelin","year":"1996","journal-title":"Clin Infect Dis"},{"key":"2022082312072164400_CIT0488","doi-asserted-by":"crossref","first-page":"bcr0620114412","DOI":"10.1136\/bcr.06.2011.4412","article-title":"Saccharomyces boulardii fungemia caused by treatment with a probioticum","volume":"2012","author":"Thygesen","year":"2012","journal-title":"BMJ Case Rep"},{"key":"2022082312072164400_CIT0489","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S0002-9270(99)00813-8","article-title":"Probiotics and immune response","volume":"95","author":"Cunningham-Rundles","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"2022082312072164400_CIT0490","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0278-6915(98)00090-8","article-title":"Safety and tolerance of Lactobacillus reuteri supplementation to a population infected with the human immunodeficiency virus","volume":"36","author":"Wolf","year":"1998","journal-title":"Food Chem Toxicol"},{"key":"2022082312072164400_CIT0491","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s100960050007","article-title":"Virulence factors of Enterococcus faecalis and Enterococcus faecium blood culture isolates","volume":"19","author":"Elsner","year":"2000","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2022082312072164400_CIT0492","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.biopha.2018.12.104","article-title":"Probiotic supplements might not be universally-effective and safe: a review","volume":"111","author":"Kothari","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"2022082312072164400_CIT0493","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1128\/AAC.35.8.1626","article-title":"Bacteremia caused by hemolytic, high-level gentamicin-resistant Enterococcus faecalis","volume":"35","author":"Huycke","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082312072164400_CIT0494","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/ecco-jcc\/jjy058","article-title":"Anti-TNF levels in cord blood at birth are associated with anti-TNF type","volume":"12","author":"Kanis","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0495","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cgh.2012.11.011","article-title":"Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease","volume":"11","author":"Mahadevan","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0496","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.cgh.2012.10.024","article-title":"Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure","volume":"11","author":"Zelinkova","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0497","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1136\/gutjnl-2015-309321","article-title":"Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety","volume":"65","author":"de Lima","year":"2016","journal-title":"Gut"},{"key":"2022082312072164400_CIT0498","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/j.gastro.2016.04.002","article-title":"Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection","volume":"151","author":"Julsgaard","year":"2016","journal-title":"Gastroenterology"},{"key":"2022082312072164400_CIT0499","doi-asserted-by":"crossref","first-page":"60","DOI":"10.7326\/L17-0629","article-title":"Prolonged persistence of adalimumab transferred from mother to infant during pregnancy","volume":"169","author":"Labetoulle","year":"2018","journal-title":"Ann Intern Med"},{"key":"2022082312072164400_CIT0500","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/ibd\/izy294","article-title":"Safety of anti-TNF-alpha therapy during pregnancy on long-term outcome of exposed children: a controlled, multicenter observation","volume":"25","author":"Duricova","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0501","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/ajg.2017.501","article-title":"Long-term safety of in utero exposure to anti-TNF\u03b1 drugs for the treatment of inflammatory bowel disease: results from the multicenter European TEDDY study","volume":"113","author":"Chaparro","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"2022082312072164400_CIT0502","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1038\/s41395-018-0176-7","article-title":"Continuous anti-TNF\u03b1 use throughout pregnancy: possible complications for the mother but not for the fetus. a Retrospective Cohort on the French National Health Insurance Database [EVASION]","volume":"113","author":"Luu","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"2022082312072164400_CIT0503","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/ajg.2013.171","article-title":"Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease","volume":"108","author":"Gisbert","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"2022082312072164400_CIT0504","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cgh.2017.08.041","article-title":"Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines","volume":"16","author":"Beaulieu","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0505","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1093\/ecco-jcc\/jjy053","article-title":"Hepatitis B vaccination effective in children exposed to anti-tumour necrosis factor alpha in utero","volume":"12","author":"de Lima","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0506","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1007\/s10620-015-3992-2","article-title":"The effect of maternal peripartum anti-TNF\u03b1 use on infant immune response","volume":"61","author":"Sheibani","year":"2016","journal-title":"Dig Dis Sci"},{"key":"2022082312072164400_CIT0507","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.3389\/fimmu.2017.01123","article-title":"Immunological changes in blood of newborns exposed to anti-TNF-\u03b1 during pregnancy","volume":"8","author":"Esteve-Sol\u00e9","year":"2017","journal-title":"Front Immunol"},{"key":"2022082312072164400_CIT0508","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/ecco-jcc\/jjx034","article-title":"Immunoglobulin and infliximab concentrations in dichorionic twins exposed to infliximab in utero","volume":"11","author":"Vestergaard","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0509","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/01.MIB.0000440984.86659.4f","article-title":"Impact of anti-tumor necrosis factor alpha antibodies administered to pregnant women with inflammatory bowel disease on long-term outcome of exposed children","volume":"20","author":"Bortlik","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"2022082312072164400_CIT0510","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1111\/apt.15504","article-title":"Safety of first year vaccination in children born to mothers with inflammatory bowel disease and exposed in utero to anti-TNF\u03b1 agents: a French nationwide population-based cohort","volume":"50","author":"Luu","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2022082312072164400_CIT0511","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.crohns.2010.05.001","article-title":"Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn\u2019s disease","volume":"4","author":"Cheent","year":"2010","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0512","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/ecco-jcc\/jju006","article-title":"The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease","volume":"9","author":"van der Woude","year":"2015","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0513","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa052664","article-title":"Safety and efficacy of a pentavalent human-bovine [WC3] reassortant rotavirus vaccine","volume":"354","author":"Vesikari","year":"2006","journal-title":"N Engl J Med"},{"key":"2022082312072164400_CIT0514","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/14760584.2019.1599286","article-title":"In utero exposure to biologic disease-modifying anti-rheumatic drugs and effects to the infant: infectious complications, vaccine response, and safety of live vaccine administration","volume":"18","author":"Berkhout","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"2022082312072164400_CIT0515","doi-asserted-by":"crossref","first-page":"237","DOI":"10.5217\/ir.2018.00071","article-title":"Influence of anti-tumor necrosis factor-alpha therapy to pregnant inflammatory bowel disease women and their children\u2019s immunity","volume":"17","author":"Lee","year":"2019","journal-title":"Intest Res"},{"key":"2022082312072164400_CIT0516","first-page":"1","article-title":"Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices [ACIP]","volume":"62","author":"McLean","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"2022082312072164400_CIT0517","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrgastro.2016.94","article-title":"IBD: exposure to anti-TNF agents in utero: controlling health risks","volume":"13","author":"van der Woude","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2022082312072164400_CIT0518","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.toxlet.2003.12.030","article-title":"Alterations in the immune system of children from mothers treated with immunosuppressive agents during pregnancy","volume":"149","author":"Cimaz","year":"2004","journal-title":"Toxicol Lett"},{"key":"2022082312072164400_CIT0519","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1177\/0961203307079569","article-title":"Immune function in children born to mothers with autoimmune diseases and exposed in utero to immunosuppressants","volume":"16","author":"Biggioggero","year":"2007","journal-title":"Lupus"},{"key":"2022082312072164400_CIT0520","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/apt.12334","article-title":"Long-term follow-up of children exposed intrauterine to maternal thiopurine therapy during pregnancy in females with inflammatory bowel disease","volume":"38","author":"de Meij","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"2022082312072164400_CIT0521","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.vaccine.2015.12.017","article-title":"Response to immunization in children born to renal transplant recipients using immunosuppressive drugs during gestation","volume":"34","author":"Dinelli","year":"2016","journal-title":"Vaccine"},{"key":"2022082312072164400_CIT0522","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.14309\/ajg.0000000000000186","article-title":"Exposure to vedolizumab in IBD pregnant women appears of low risk for mother and neonate: a first prospective comparison study","volume":"114","author":"Bar-Gil Shitrit","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"2022082312072164400_CIT0523","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/apt.14837","article-title":"Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease","volume":"48","author":"Julsgaard","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2022082312072164400_CIT0524","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/ecco-jcc\/jjx141","article-title":"Ustekinumab drug levels in maternal and cord blood in a woman with Crohn\u2019s disease treated until 33 weeks of gestation","volume":"12","author":"Rowan","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0525","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/ecco-jcc\/jjy153","article-title":"Drug levels in the maternal serum, cord blood and breast milk of a ustekinumab-treated patient with Crohn\u2019s disease","volume":"13","author":"Klenske","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0526","doi-asserted-by":"crossref","first-page":"e12951","DOI":"10.1111\/tid.12951","article-title":"Safe administration of rotavirus vaccine in a cohort of infants exposed to immunosuppressive drugs during gestation","volume":"20","author":"Dinelli","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"2022082312072164400_CIT0527","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/ajg.2011.5","article-title":"TNF-\u03b1 and the development of the neonatal immune system: implications for inhibitor use in pregnancy","volume":"106","author":"Arsenescu","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2022082312072164400_CIT0528","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.crohns.2011.05.006","article-title":"Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease","volume":"5","author":"Ben-Horin","year":"2011","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0529","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.crohns.2013.09.003","article-title":"Infliximab concentrations in the milk of nursing mothers with inflammatory bowel disease","volume":"8","author":"Grosen","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2022082312072164400_CIT0530","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1053\/j.gastro.2018.05.040","article-title":"Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development","volume":"155","author":"Matro","year":"2018","journal-title":"Gastroenterology"},{"key":"2022082312072164400_CIT0531","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1542\/peds.2004-2491","article-title":"Breastfeeding and the use of human milk","volume":"115","author":"Gartner","year":"2005","journal-title":"Pediatrics"},{"key":"2022082312072164400_CIT0532","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/archpedi.1978.02120300037006","article-title":"Fatal rotavirus gastroenteritis: an analysis of 21 cases","volume":"132","author":"Carlson","year":"1978","journal-title":"Am J Dis Child"},{"key":"2022082312072164400_CIT0533","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/apt.14926","article-title":"Risk of serious infection in health care workers with inflammatory bowel disease: a case-control study of the Groupe d\u2019Etude Th\u00e9rapeutique des Affections Inflammatoires du tube Digestif [GETAID]","volume":"48","author":"Gagni\u00e8re","year":"2018","journal-title":"Aliment Pharmacol Ther"}],"updated-by":[{"DOI":"10.1093\/ecco-jcc\/jjab227","type":"expression_of_concern","label":"Expression of concern","source":"retraction-watch","updated":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"record-id":"35178"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjab052\/36627606\/jjab052.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/15\/6\/879\/45500342\/jjab052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/15\/6\/879\/45500342\/jjab052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T02:59:52Z","timestamp":1698029992000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/15\/6\/879\/6175313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,17]]},"references-count":533,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,3,17]]},"published-print":{"date-parts":[[2021,6,22]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab052","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,1]]},"published":{"date-parts":[[2021,3,17]]}}}